RSS-Feed abonnieren
DOI: 10.1055/s-0028-1109062
© Georg Thieme Verlag KG Stuttgart · New York
S3-Leitlinie „Helicobacter pylori und gastroduodenale Ulkuskrankheit” der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)
in Zusammenarbeit mit der Deutschen Gesellschaft für Hygiene und Mikrobiologie, Gesellschaft für Pädiatrische Gastroenterologie und Ernährung e. V. und der Deutschen Gesellschaft für Rheumatologie – AWMF-Register-Nr. 021 / 001S3-Guideline “Helicobacter Pylori and Gastroduodenal Ulcer Disease”Publikationsverlauf
Publikationsdatum:
20. Januar 2009 (online)

Zusammenfassung
Die Leitlinie akualisiert eine frühere Konsensusempfehlung der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) aus dem Jahr 1996. Sie wurde interdisziplinär in Zusammenarbeit mit Vertretern der Deutschen Gesellschaft für Hygiene und Mikrobiologie, der Gesellschaft für Pädiatrische Gastroenterologie und Ernährung e. V. und der Deutschen Gesellschaft für Rheumatologie erstellt. Die Leitlinie basiert auf den Empfehlungen der Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) für eine systematische evidenzbasierte Konsensus-Leitlinie der Entwicklungsstufe S 3 und hat auch die Bewertungskriterien der GRADE (Grading of Recommendations Assessment, Development and Evaluation) implemetiert. Die Anwendbarkeit der Studienergebnisse und spezifische Gegebenheiten in Deutschland im Hinblick auf Epidemiologie, Resistenzlage, Diagnostik und Therapie wurden berücksichtigt.
Abstract
This guideline updates a prior concensus recommendation of the German Society for Digestive and Metabolic Diseases (DGVS) from 1996. It was developed by an interdisciplinary cooperation with representatives of the German Society for Microbiology, the Society for Pediatric Gastroenterology and Nutrition (GPGE) and the German Society for Rheumatology. The guideline is methodologically based on recommendations of the Association of the Scientific Medical Societies in Germany (AWMF) for providing a systematic evidence-based consensus guideline of S 3 level and has also implemented grading criteria according to GRADE (Grading of Recommendations Assessment, Development and Evaluation). Clinical applicability of study results as well as specifics for Germany in terms of epidemiology, antibiotic resistance status, diagnostics and therapy were taken into account.
Schlüsselwörter
Helicobacter pylori - gastroduodenale Ulzera - Ulkuskrankheit
Key words
Helicobacter pylori - gastroduodenal ulcer - ulcer disease
Literatur
- 1
Preiß J C, Timmer A, Zeitz M. et al .
Neue Konzepte der Leitlinienmethodik.
Z Gastroenterol.
2007;
45
1075-1081
MissingFormLabel
- 2
Graham D Y, Adam E, Reddy G T. et al .
Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing
and developed countries.
Dig Dis Sci.
1991;
36 (8)
1084-1088
MissingFormLabel
- 3
Megraud F, Brassens-Rabbe M P, Denis F. et al .
Seroepidemiology of Campylobacter pylori infection in various populations.
J Clin Microbiol.
1989;
27 (8)
1870-1873
MissingFormLabel
- 4
Redlinger T, O’Rourke K, Goodman K J.
Age distribution of Helicobacter pylori seroprevalence among young children in a United
States/Mexico border community: evidence for transitory infection.
Am J Epidemiol.
1999;
150 (3)
225-230
MissingFormLabel
- 5
Taylor D N, Blaser M J.
The epidemiology of Helicobacter pylori infection.
Epidemiol Rev.
1991;
13
42-59
MissingFormLabel
- 6
Malaty H M, Graham D Y.
Importance of childhood socioeconomic status on the current prevalence of Helicobacter
pylori infection.
Gut.
1994;
35 (6)
742-745
MissingFormLabel
- 7
Graham D Y, Malaty H M, Evans D G. et al .
Epidemiology of Helicobacter pylori in an asymptomatic population in the United States.
Effect of age, race, and socioeconomic status.
Gastroenterology.
1991;
100 (6)
1495-1501
MissingFormLabel
- 8
Malaty H M, Evans D G, Evans D J. et al .
Helicobacter pylori in Hispanics: comparison with blacks and whites of similar age
and socioeconomic class.
Gastroenterology.
1992;
103 (3)
813-816
MissingFormLabel
- 9
Malaty H M, Engstrand Jr L, Pedersen N L. et al .
Helicobacter pylori infection: genetic and environmental influences. A study of twins.
Ann Intern Med.
1994;
120 (12)
982-986
MissingFormLabel
- 10
Perez-Perez G I, Olivares A Z, Foo F Y. et al .
Seroprevalence of Helicobacter pylori in New York City populations originating in
East Asia.
J Urban Health.
2005;
82 (3)
510-516
MissingFormLabel
- 11
Malaty H M, Kim J G, Kim S D. et al .
Prevalence of Helicobacter pylori infection in Korean children: inverse relation to
socioeconomic status despite a uniformly high prevalence in adults.
Am J Epidemiol.
1996;
143 (3)
257-262
MissingFormLabel
- 12
Banatvala N, Mayo K, Megraud F. et al .
The cohort effect and Helicobacter pylori.
J Infect Dis.
1993;
168 (1)
219-221
MissingFormLabel
- 13
Roosendaal R, Kuipers E J, Buitenwerf J. et al .
Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease
of infection rates in childhood.
Am J Gastroenterol.
1997;
92 (9)
1480-1482
MissingFormLabel
- 14
al-Moagel M A, Evans D G, Abdulghani M E. et al .
Prevalence of Helicobacter (formerly Campylobacter) pylori infection in Saudia Arabia,
and comparison of those with and without upper gastrointestinal symptoms.
Am J Gastroenterol.
1990;
85 (8)
944-948
MissingFormLabel
- 15
Grimm W, Fischbach W.
Helicobacter pylori infection in children and juveniles: an epidemiological study
on prevalence, socio-economic factors and symptoms.
Dtsch Med Wochenschr.
2003;
128 (37)
1878-1883
MissingFormLabel
- 16
Rothenbacher D, Bode G, Berg G. et al .
Prevalence and determinants of Helicobacter pylori infection in preschool children:
a population-based study from Germany.
Int J Epidemiol.
1998;
27 (1)
135-141
MissingFormLabel
- 17
Brenner H, Weyermann M, Rothenbacher D.
Clustering of Helicobacter pylori infection in couples: differences between high-
and low-prevalence population groups.
Ann Epidemiol.
2006;
16 (7)
516-520
MissingFormLabel
- 18
Kumagai T, Malaty H M, Graham D Y. et al .
Acquisition versus loss of Helicobacter pylori infection in Japan: results from an
8-year birth cohort study.
J Infect Dis.
1998;
178 (3)
717-721
MissingFormLabel
- 19
Tkachenko M A, Zhannat N Z, Erman L V. et al .
Dramatic Changes in the Prevalence of Helicobacter pylori Infection During Childhood:
A 10-year Follow-up Study in Russia.
J Pediatr Gastroenterol Nutr.
2007;
45 (4)
428-432
MissingFormLabel
- 20
Parsonnet J.
The incidence of Helicobacter pylori infection.
Aliment Pharmacol Ther.
1995;
9 (Suppl 2)
45-51
MissingFormLabel
- 21
Parsonnet J, Shmuely H, Haggerty T.
Fecal and oral shedding of Helicobacter pylori from healthy infected adults.
Jama.
1999;
282 (23)
2240-2245
MissingFormLabel
- 22
Leung W K, Siu K L, Kwok C K. et al .
Isolation of Helicobacter pylori from vomitus in children and its implication in gastro-oral
transmission.
Am J Gastroenterol.
1999;
94 (10)
2881-2884
MissingFormLabel
- 23
Laporte R, Pernes P, Pronnier P. et al .
Acquisition of Helicobacter pylori infection after outbreaks of gastroenteritis: prospective
cohort survey in institutionalised young people.
Bmj.
2004;
329 (7459)
204-205
MissingFormLabel
- 24
Handt L K, Fox J G, Dewhirst F E. et al .
Helicobacter pylori isolated from the domestic cat: public health implications.
Infect Immun.
1994;
62 (6)
2367-2374
MissingFormLabel
- 25
Dore M P, Sepulveda A R, Osato M S. et al .
Helicobacter pylori in sheep milk.
Lancet.
1999;
354 (9173)
132
MissingFormLabel
- 26
Dore M P, Sepulveda A R, El-Zimaity H. et al .
Isolation of Helicobacter pylori from sheep-implications for transmission to humans.
Am J Gastroenterol.
2001;
96 (5)
1396-1401
MissingFormLabel
- 27
Rocha G A, Rocha A M, Silva L D. et al .
Transmission of Helicobacter pylori infection in families of preschool-aged children
from Minas Gerais, Brazil.
Trop Med Int Health.
2003;
8 (11)
987-991
MissingFormLabel
- 28
Rothenbacher D, Winkler M, Gonser T. et al .
Role of infected parents in transmission of helicobacter pylori to their children.
Pediatr Infect Dis J.
2002;
21 (7)
674-679
MissingFormLabel
- 29
Kivi M, Johansson A L, Reilly M. et al .
Helicobacter pylori status in family members as risk factors for infection in children.
Epidemiol Infect.
2005;
133 (4)
645-652
MissingFormLabel
- 30
Tindberg Y, Bengtsson C, Granath F. et al .
Helicobacter pylori infection in Swedish school children: lack of evidence of child-to-child
transmission outside the family.
Gastroenterology.
2001;
121 (2)
310-316
MissingFormLabel
- 31
Han S R, Zschausch H C, Meyer H G. et al .
Helicobacter pylori: clonal population structure and restricted transmission within
families revealed by molecular typing.
J Clin Microbiol.
2000;
38 (10)
3646-3651
MissingFormLabel
- 32
Kivi M, Tindberg Y, Sorberg M. et al .
Concordance of Helicobacter pylori strains within families.
J Clin Microbiol.
2003;
41 (12)
5604-5608
MissingFormLabel
- 33
Mendall M A, Goggin P M, Molineaux N. et al .
Childhood living conditions and Helicobacter pylori seropositivity in adult life.
Lancet.
1992;
339 (8798)
896-897
MissingFormLabel
- 34
Goodman K J, Correa P.
Transmission of Helicobacter pylori among siblings.
Lancet.
2000;
355 (9201)
358-362
MissingFormLabel
- 35
Rowland M, Daly L, Vaughan M. et al .
Age-specific incidence of Helicobacter pylori.
Gastroenterology.
2006;
130 (1)
65-72; quiz 211
MissingFormLabel
- 36
Goodman K J, Correa P, Tengana Aux H J. et al .
Helicobacter pylori infection in the Colombian Andes: a population-based study of
transmission pathways.
Am J Epidemiol.
1996;
144 (3)
290-299
MissingFormLabel
- 37
Glynn M K, Friedman C R, Gold B D. et al .
Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children:
acquisition and analysis of possible risk factors.
Clin Infect Dis.
2002;
35 (9)
1059-1065
MissingFormLabel
- 38
Aguemon B D, Struelens M J, Massougbodji A. et al .
Prevalence and risk-factors for Helicobacter pylori infection in urban and rural Beninese
populations.
Clin Microbiol Infect.
2005;
11 (8)
611-617
MissingFormLabel
- 39
Klein P D, Graham D Y, Gaillour A. et al .
Water source as risk factor for Helicobacter pylori infection in Peruvian children.
Gastrointestinal Physiology Working Group.
Lancet.
1991;
337 (8756)
1503-1506
MissingFormLabel
- 40
Hulten K, Han S W, Enroth H. et al .
Helicobacter pylori in the drinking water in Peru.
Gastroenterology.
1996;
110 (4)
1031-1035
MissingFormLabel
- 41
Lu Y, Redlinger T E, Avitia R. et al .
Isolation and genotyping of Helicobacter pylori from untreated municipal wastewater.
Appl Environ Microbiol.
2002;
68 (3)
1436-1439
MissingFormLabel
- 42
Tomb J F, White O, Kerlavage A R. et al .
The complete genome sequence of the gastric pathogen Helicobacter pylori.
Nature.
1997;
388 (6642)
539-547
MissingFormLabel
- 43
Wheeldon T U, Hoang T T, Phung D C. et al .
Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection
and clinical outcome.
Aliment Pharmacol Ther.
2005;
21 (8)
1047-1053
MissingFormLabel
- 44
Feydt-Schmidt A, Kindermann A, Konstantopoulos N. et al .
Reinfection rate in children after successful Helicobacter pylori eradication.
Eur J Gastroenterol Hepatol.
2002;
14 (10)
1119-1123
MissingFormLabel
- 45
Svennerholm A M, Lundgren A.
Progress in vaccine development against Helicobacter pylori.
FEMS Immunol Med Microbiol.
2007;
50 (2)
146-156
MissingFormLabel
- 46
Wilson K T, Crabtree J E.
Immunology of Helicobacter pylori: insights into the failure of the immune response
and perspectives on vaccine studies.
Gastroenterology.
2007;
133 (1)
288-308
MissingFormLabel
- 47
Kivi M, Tindberg Y.
Helicobacter pylori occurrence and transmission: a family affair?.
Scand J Infect Dis.
2006;
38 (6 – 7)
407-417
MissingFormLabel
- 48
Kuepper-Nybelen J, Thefeld W, Rothenbacher D. et al .
Patterns of alcohol consumption and Helicobacter pylori infection: results of a population-based
study from Germany among 6545 adults.
Aliment Pharmacol Ther.
2005;
21 (1)
57-64
MissingFormLabel
- 49
Metzger W G, Mansouri E, Kronawitter M. et al .
Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica
serovar typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in
human volunteers.
Vaccine.
2004;
22 (17 – 18)
2273-2277
MissingFormLabel
- 50
Graham D Y, Opekun A R, Osato M S. et al .
Challenge model for Helicobacter pylori infection in human volunteers.
Gut.
2004;
53 (9)
1235-1243
MissingFormLabel
- 51
Losonsky G A, Kotloff K L, Walker R I.
B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter
pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals.
Vaccine.
2003;
21 (5 – 6)
562-565
MissingFormLabel
- 52
Banerjee S, Medina-Fatimi A, Nichols R. et al .
Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based
oral immunisation against Helicobacter pylori in healthy volunteers.
Gut.
2002;
51 (5)
634-640
MissingFormLabel
- 53
Rupnow M F, Shachter R D, Owens D K. et al .
Quantifying the population impact of a prophylactic Helicobacter pylori vaccine.
Vaccine.
2001;
20 (5 – 6)
879-885
MissingFormLabel
- 54
Kotloff K L, Sztein M B, Wasserman S S. et al .
Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine
with adjuvant among volunteers with or without subclinical infection.
Infect Immun.
2001;
69 (6)
3581-3590
MissingFormLabel
- 55
Bumann D, Metzger W G, Mansouri E. et al .
Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a
expressing urease A and B from Helicobacter pylori in human volunteers.
Vaccine.
2001;
20 (5 – 6)
845-852
MissingFormLabel
- 56
Angelakopoulos H, Hohmann E L.
Pilot study of phoP/phoQ-deleted Salmonella terica serovar typhimurium expressing
Helicobacter pylori urease in adult volunteers.
Infect Immun.
2000;
68 (4)
2135-2141
MissingFormLabel
- 57
Rupnow M F, Owens D K, Shachter R. et al .
Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using
the Institute of Medicine Methodology.
Helicobacter.
1999;
4 (4)
272-280
MissingFormLabel
- 58
Michetti P, Kreiss C, Kotloff K L. et al .
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe
and immunogenic in Helicobacter pylori-infected adults.
Gastroenterology.
1999;
116 (4)
804-812
MissingFormLabel
- 59
DiPetrillo M D, Tibbetts T, Kleanthous H. et al .
Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter
pylori urease in adult volunteers.
Vaccine.
1999;
18 (5 – 6)
449-459
MissingFormLabel
- 60
Forman D, Newell D G, Fullerton F. et al .
Association between infection with Helicobacter pylori and risk of gastric cancer:
evidence from a prospective investigation.
Bmj.
1991;
302 (6788)
1302-1305
MissingFormLabel
- 61
Forman D, Sitas F, Newell D G. et al .
Geographic association of Helicobacter pylori antibody prevalence and gastric cancer
mortality in rural China.
Int J Cancer.
1990;
46 (4)
608-611
MissingFormLabel
- 62
Stolte M, Eidt S.
Lymphoid follicles in antral mucosa: immune response to Campylobacter pylori?.
J Clin Pathol.
1989;
42 (12)
1269-1271
MissingFormLabel
- 63
NIH Consensus Conference .
Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter
pylori in Peptic Ulcer Disease.
Jama.
1994;
272 (1)
65-69
MissingFormLabel
- 64
Peura D A, Graham D Y.
Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an
historic disease.
Am J Gastroenterol.
1994;
89 (8)
1137-1139
MissingFormLabel
- 65
Nomura A, Stemmermann G N, Chyou P H. et al .
Helicobacter pylori infection and the risk for duodenal and gastric ulceration.
Ann Intern Med.
1994;
120 (12)
977-981
MissingFormLabel
- 66
Huang J Q, Sridhar S, Chen Y. et al .
Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric
cancer.
Gastroenterology.
1998;
114 (6)
1169-1179
MissingFormLabel
- 67
Danesh J.
Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological
studies.
Aliment Pharmacol Ther.
1999;
13 (7)
851-856
MissingFormLabel
- 68
Eslick G D, Lim L L, Byles J E. et al .
Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis.
Am J Gastroenterol.
1999;
94 (9)
2373-2379
MissingFormLabel
- 69
Xue F B, Xu Y Y, Wan Y. et al .
Association of H. pylori infection with gastric carcinoma: a Meta analysis.
World J Gastroenterol.
2001;
7 (6)
801-804
MissingFormLabel
- 70
Huang J Q, Zheng G F, Sumanac K. et al .
Meta-analysis of the relationship between cagA seropositivity and gastric cancer.
Gastroenterology.
2003;
125 (6)
1636-1644
MissingFormLabel
- 71
Helicobacter and Cancer Collaborative Group .
Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies
nested within prospective cohorts.
Gut.
2001;
49 (3)
347-353
MissingFormLabel
- 72
Brenner H, Arndt V, Stegmaier C. et al .
Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer?.
Am J Epidemiol.
2004;
159 (3)
252-258
MissingFormLabel
- 73
Parsonnet J, Hansen S, Rodriguez L. et al .
Helicobacter pylori infection and gastric lymphoma.
N Engl J Med.
1994;
330 (18)
1267-1271
MissingFormLabel
- 74
Lehours P, Dupouy S, Bergey B. et al .
Identification of a genetic marker of Helicobacter pylori strains involved in gastric
extranodal marginal zone B cell lymphoma of the MALT-type.
Gut.
2004;
53 (7)
931-937
MissingFormLabel
- 75
Solnick J V, Schauer D B.
Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic
diseases.
Clin Microbiol Rev.
2001;
14 (1)
59-97
MissingFormLabel
- 76
Morgner A, Lehn N, Andersen L P. et al .
Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete
remission after curing the infection.
Gastroenterology.
2000;
118 (5)
821-828
MissingFormLabel
- 77
Noone P A, Waclawski E R, Watt A D.
Are endoscopy nurses at risk of infection with Helicobacter pylori from their work?.
Occup Med.
2006;
56 (2)
122-128
MissingFormLabel
- 78
Mastromarino P, Conti C, Donato K. et al .
Does hospital work constitute a risk factor for Helicobacter pylori infection?.
J Hosp Infect.
2005;
60 (3)
261-268
MissingFormLabel
- 79
Matsuda R, Morizane T.
Helicobacter pylori infection in dental professionals: a 6-year prospective study.
Helicobacter.
2005;
10 (4)
307-311
MissingFormLabel
- 80
Kim N, Lim S H, Lee K H. et al .
Seroconversion of Helicobacter pylori in Korean male employees.
Scand J Gastroenterol.
2005;
40 (9)
1021-1027
MissingFormLabel
- 81
Braden B, Duan L P, Caspary W F. et al .
Endoscopy is not a risk factor for Helicobacter pylori infection– but medical practice
is.
Gastrointest Endosc.
1997;
46 (4)
305-310
MissingFormLabel
- 82
Cutler A F, Havstad S, Ma C K. et al .
Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection.
Gastroenterology.
1995;
109 (1)
136-141
MissingFormLabel
- 83
Thijs J C, Zwet A A, Thijs W J. et al .
Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy,
without selecting a single test as the gold standard.
Am J Gastroenterol.
1996;
91 (10)
2125-2129
MissingFormLabel
- 84
Laheij R J, Boer de W A, Jansen J B. et al .
Diagnostic performance of biopsy-based methods for determination of Helicobacter pylori
infection without a reference standard.
J Clin Epidemiol.
2000;
53 (7)
742-746
MissingFormLabel
- 85
Juttner van S, Vieth M, Miehlke S. et al .
Reliable detection of macrolide-resistant Helicobacter pylori via fluorescence in
situ hybridization in formalin-fixed tissue.
Mod Pathol.
2004;
17 (6)
684-689
MissingFormLabel
- 86
Lottspeich C, Schwarzer A, Panthel K. et al .
Evaluation of the novel Helicobacter pylori ClariRes real-time PCR assay for detection
and clarithromycin susceptibility testing of H. pylori in stool specimens from symptomatic
children.
J Clin Microbiol.
2007;
45 (6)
1718-1722
MissingFormLabel
- 87
Gisbert J P, Pajares J M.
Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection
– a critical review.
Aliment Pharmacol Ther.
2004;
20 (10)
1001-1017
MissingFormLabel
- 88
Leodolter A, Dominguez-Munoz J E, Arnim von U. et al .
Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of
Helicobacter pylori infection in the routine clinical setting.
Am J Gastroenterol.
1999;
94 (8)
2100-2104
MissingFormLabel
- 89
Gisbert J P, Morena de la F, Abraira V.
Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection:
a systematic review and meta-analysis.
Am J Gastroenterol.
2006;
101 (8)
1921-1930
MissingFormLabel
- 90
Feldman R A, Deeks J J, Evans S J.
Multi-laboratory comparison of eight commercially available Helicobacter pylori serology
kits. Helicobacter pylori Serology Study Group.
Eur J Clin Microbiol Infect Dis.
1995;
14 (5)
428-433
MissingFormLabel
- 91
Loy C T, Irwig L M, Katelaris P H. et al .
Do commercial serological kits for Helicobacter pylori infection differ in accuracy?
A meta-analysis.
Am J Gastroenterol.
1996;
91 (6)
1138-1144
MissingFormLabel
- 92
Bayerdorffer E, Oertel H, Lehn N. et al .
Topographic association between active gastritis and Campylobacter pylori colonisation.
J Clin Pathol.
1989;
42 (8)
834-839
MissingFormLabel
- 93
Dixon M F, Genta R M, Yardley J H. et al .
Classification and grading of gastritis. The updated Sydney System. International
Workshop on the Histopathology of Gastritis, Houston 1994.
Am J Surg Pathol.
1996;
20 (10)
1161-1181
MissingFormLabel
- 94
Stolte M, Muller H, Talley N J. et al .
In patients with Helicobacter pylori gastritis and functional dyspepsia, a biopsy
from the incisura angularis provides useful diagnostic information.
Pathol Res Pract.
2006;
202 (6)
405-413
MissingFormLabel
- 95
Guidelines for clinical trials in Helicobacter pylori infection. Working Party of
the European Helicobacter pylori Study Group.
Gut.
1997;
41 (Suppl 2)
S1-S9
MissingFormLabel
- 96
Megraud F, Lehours P.
Helicobacter pylori detection and antimicrobial susceptibility testing.
Clin Microbiol Rev.
2007;
20 (2)
280-322
MissingFormLabel
- 97
Woo J S, El Zimaity H M, Genta R M. et al .
The best gastric site for obtaining a positive rapid ureas test.
Helicobacter.
1996;
1 (4)
256-259
MissingFormLabel
- 98
Tepes B.
Comparison of two invasive diagnostic tests for Helicobacter pylori after antimicrobial
therapy.
Scand J Gastroenterol.
2007;
42 (3)
330-332
MissingFormLabel
- 99
IJzendoorn M C, Laheij R J, Boer de W A. et al .
The importance of corpus biopsies for the determination of Helicobacter pylori infection.
Neth J Med.
2005;
63 (4)
141-145
MissingFormLabel
- 100
Leodolter van A, Vaira D, Bazzoli F. et al .
European multicentre validation trial of two new non-invasive tests for the detection
of Helicobacter pylori antibodies: urine-based ELISA and rapid urine test.
Aliment Pharmacol Ther.
2003;
18 (9)
927-931
MissingFormLabel
- 101
Hackelsberger A, Schultze V, Peitz U. et al .
Performance of a rapid whole blood test for Helicobacter pylori in primary care: a
German multicenter study.
Helicobacter.
1998;
3 (3)
179-183
MissingFormLabel
- 102
Peitz U, Baumann M, Tillenburg B. et al .
(Insufficient validity of a rapid blood test for diagnosis of Helicobacter pylori
infection).
Med Klin.
2001;
96 (12)
703-707
MissingFormLabel
- 103
Hoang T T, Rehnberg A S, Wheeldon T U. et al .
Comparison of the performance of serological kits for Helicobacter pylori infection
with European and Asian study populations.
Clin Microbiol Infect.
2006;
12 (11)
1112-1117
MissingFormLabel
- 104
Suerbaum S, Achtman M.
Helicobacter pylori: recombination, population structure and human migrations.
Int J Med Microbiol.
2004;
294 (2 – 3)
133-139
MissingFormLabel
- 105
Ekstrom A M, Held M, Hansson L E. et al .
Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of
past infection.
Gastroenterology.
2001;
121 (4)
784-791
MissingFormLabel
- 106
Capurso G, Carnuccio A, Lahner E. et al .
Corpus-predominant gastritis as a risk factor for false-negative 13C-urea breath test
results.
Aliment Pharmacol Ther.
2006;
24 (10)
1453-1460
MissingFormLabel
- 107
Kokkola A, Rautelin H, Puolakkainen P. et al .
Diagnosis of Helicobacter pylori infection in patients with atrophic gastritis: comparison
of histology, 13C-urea breath test, and serology.
Scand J Gastroenterol.
2000;
35 (2)
138-141
MissingFormLabel
- 108
Korstanje A, Eeden van S, Offerhaus G J. et al .
The 13carbon urea breath test for the diagnosis of Helicobacter pylori infection in
subjects with atrophic gastritis: evaluation in a primary care setting.
Aliment Pharmacol Ther.
2006;
24 (4)
643-650
MissingFormLabel
- 109
Lahner E, Vaira D, Figura N. et al .
Role of noninvasive tests (C-urea breath test and stool antigen test) as additional
tools in diagnosis of Helicobacter pylori infection in patients with atrophic body
gastritis.
Helicobacter.
2004;
9 (5)
436-442
MissingFormLabel
- 110
Lehours P, Ruskone-Fourmestraux A, Lavergne A. et al .
Which test to use to detect Helicobacter pylori infection in patients with low-grade
gastric mucosa-associated lymphoid tissue lymphoma?.
Am J Gastroenterol.
2003;
98 (2)
291-295
MissingFormLabel
- 111
Schilling D, Jakobs R, Peitz U. et al .
Diagnostic accuracy of (13)C-urea breath test in the diagnosis of Helicobacter pylori
infection in patients with partial gastric resection due to peptic ulcer disease:
a prospective multicenter study.
Digestion.
2001;
63 (1)
8-13
MissingFormLabel
- 112
Laine L A, Nathwani R A, Naritoku W.
The effect of GI bleeding on Helicobacter pylori diagnostic testing: a prospective
study at the time of bleeding and 1 month later.
Gastrointest Endosc.
2005;
62 (6)
853-859
MissingFormLabel
- 113
Lee J M, Breslin N P, Fallon C. et al .
Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer
disease presents with bleeding.
Am J Gastroenterol.
2000;
95 (5)
1166-1170
MissingFormLabel
- 114
Peitz U, Leodolter A, Wex T. et al .
Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding.
Z Gastroenterol.
2004;
42 (2)
141-146
MissingFormLabel
- 115
Gisbert J P, Abraira V.
Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic
ulcer: a systematic review and meta-analysis.
Am J Gastroenterol.
2006;
101 (4)
848-863
MissingFormLabel
- 116
Schilling D, Demel A, Adamek H E. et al .
A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection
during acute phase of ulcer bleeding. A prospective case control study.
Dig Liver Dis.
2003;
35 (4)
217-221
MissingFormLabel
- 117
Brandi G, Biavati B, Calabrese C. et al .
Urease-positive bacteria other than Helicobacter pylori in human gastric juice and
mucosa.
Am J Gastroenterol.
2006;
101 (8)
1756-1761
MissingFormLabel
- 118
Urita Y, Hike K, Torii N. et al .
Influence of urease activity in the intestinal tract on the results of 13C-urea breath
test.
J Gastroenterol Hepatol.
2006;
21 (4)
744-747
MissingFormLabel
- 119
MacOni G, Vago L, Galletta G. et al .
Is routine histological evaluation an accurate test for Helicobacter pylori infection?.
Aliment Pharmacol Ther.
1999;
13 (3)
327-331
MissingFormLabel
- 120
Stolte M, Wellens E, Bethke B. et al .
Helicobacter heilmannii (formerly Gastrospirillum hominis) gastritis: an infection
transmitted by animals?.
Scand J Gastroenterol.
1994;
29 (12)
1061-1064
MissingFormLabel
- 121
Chey W D, Woods M, Scheiman J M. et al .
Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent
mechanism.
Am J Gastroenterol.
1997;
92 (3)
446-450
MissingFormLabel
- 122
Laine L, Estrada R, Trujillo M. et al .
Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori.
Ann Intern Med.
1998;
129 (7)
547-550
MissingFormLabel
- 123
Gatta L, Vakil N, Ricci C. et al .
Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and
stool test for Helicobacter pylori infection.
Am J Gastroenterol.
2004;
99 (5)
823-829
MissingFormLabel
- 124
Graham D Y, Opekun A R, Hammoud F. et al .
Studies regarding the mechanism of false negative urea breath tests with proton pump
inhibitors.
Am J Gastroenterol.
2003;
98 (5)
1005-1009
MissingFormLabel
- 125
Levine A, Shevah O, Shabat-Sehayek V. et al .
Masking of 13C urea breath test by proton pump inhibitors is dependent on type of
medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
Aliment Pharmacol Ther.
2004;
20 (1)
117-122
MissingFormLabel
- 126
Mana F, Van Laere W, Bossuyt A. et al .
The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea
breath test.
Dig Liver Dis.
2005;
37 (1)
28-32
MissingFormLabel
- 127
Manes G, Balzano A, Iaquinto G. et al .
Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection
before treatment and in patients on omeprazole therapy.
Aliment Pharmacol Ther.
2001;
15 (1)
73-79
MissingFormLabel
- 128
Malfertheiner P, Megraud F, O’Morain C. et al .
Current concepts in the management of Helicobacter pylori infection: the Maastricht
III Consensus Report.
Gut.
2007;
56 (6)
772-781
MissingFormLabel
- 129
Stolte M, Stadelmann O, Bethke B. et al .
Relationships between the degree of Helicobacter pylori colonisation and the degree
and activity of gastritis, surface epithelial degeneration and mucus secretion.
Z Gastroenterol.
1995;
33 (2)
89-93
MissingFormLabel
- 130
Grimley C E, Holder R L, Loft D E. et al .
Helicobacter pylori-associated antibodies in patients with duodenal ulcer, gastric
and oesophageal adenocarcinoma.
Eur J Gastroenterol Hepatol.
1999;
11 (5)
503-509
MissingFormLabel
- 131
Han S R, Schneider T, Loos M. et al .
One-step polymerase chain reaction-based typing of Helicobacter pylori vacA gene:
association with gastric histopathology.
Med Microbiol Immunol.
1999;
188 (3)
131-138
MissingFormLabel
- 132
Lamarque D, Gilbert T, Roudot-Thoraval F. et al .
Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic
ulcer, MALT gastric lymphoma or non-ulcer dyspepsia. Higher rate of seroreactivity
against CagA and 35-kDa antigens in patients with peptic ulcer originating from Europe
and Africa.
Eur J Gastroenterol Hepatol.
1999;
11 (7)
721-726
MissingFormLabel
- 133
Plummer M, Doorn L J, Franceschi van S. et al .
Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions.
J Natl Cancer Inst.
2007;
99 (17)
1328-1334
MissingFormLabel
- 134
Scholte G H, Doorn L J, Cats van A. et al .
Genotyping of Helicobacter pylori in paraffin-embedded gastric biopsy specimens: relation
to histological parameters and effects on therapy.
Am J Gastroenterol.
2002;
97 (7)
1687-1695
MissingFormLabel
- 135
Kodama K, Ito A, Nishizono A. et al .
Divergence of virulence factors of Helicobacter pylori among clinical isolates does
not correlate with disease specificity.
J Gastroenterol.
1999;
34 (Suppl 11)
6-9
MissingFormLabel
- 136
Breuer T, Graham D Y.
Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing
the treatment regimen based on susceptibility testing become cost effective?.
Am J Gastroenterol.
1999;
94 (3)
725-729
MissingFormLabel
- 137
Romano M, Marmo R, Cuomo A. et al .
Pretreatment antimicrobial susceptibility testing is cost saving in the eradication
of Helicobacter pylori.
Clin Gastroenterol Hepatol.
2003;
1 (4)
273-278
MissingFormLabel
- 138
Marzio L, Coraggio D, Capodicasa S. et al .
Role of the preliminary susceptibility testing for initial and after failed therapy
of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole.
Helicobacter.
2006;
11 (4)
237-242
MissingFormLabel
- 139
Malfertheiner P, Peitz U, Wolle K. et al .
Helicobacter pylori infection – an update for 2004.
Dtsch Med Wochenschr.
2004;
129 (34 – 35)
1821-1826
MissingFormLabel
- 140
Best L M, Haldane D J, Keelan M. et al .
Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter
pylori and correlation between agar dilution and E test methods.
Antimicrob Agents Chemother.
2003;
47 (10)
3138-3144
MissingFormLabel
- 141
Grignon B, Tankovic J, Megraud F. et al .
Validation of diffusion methods for macrolide susceptibility testing of Helicobacter
pylori.
Microb Drug Resist.
2002;
8 (1)
61-66
MissingFormLabel
- 142
Perna F, Gatta L, Figura N. et al .
Susceptibility of Helicobacter pylori to metronidazole.
Am J Gastroenterol.
2003;
98 (10)
2157-2161
MissingFormLabel
- 143
Ford A C, Delaney B C, Forman D. et al .
Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients.
Cochrane Database Syst Rev.
2006;
2
CD003840
MissingFormLabel
- 144
Laine L, Hopkins R J, Girardi L S.
Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States
been overstated? A meta-analysis of rigorously designed trials.
Am J Gastroenterol.
1998;
93 (9)
1409-1415
MissingFormLabel
- 145
Leodolter A, Kulig M, Brasch H. et al .
A meta-analysis comparing eradication, healing and relapse rates in patients with
Helicobacter pylori-associated gastric or duodenal ulcer.
Aliment Pharmacol Ther.
2001;
15 (12)
1949-1958
MissingFormLabel
- 146
Liu C C, Lee C L, Chan C C. et al .
Maintenance treatment is not necessary after Helicobacter pylori eradication and healing
of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
Arch Intern Med.
2003;
163 (17)
2020-2024
MissingFormLabel
- 147
Malfertheiner P, Megraud F, O’Morain C. et al .
Current concepts in the management of Helicobacter pylori infection: the Maastricht
III Consensus Report.
Gut.
2007;
56 (6)
772-781
MissingFormLabel
- 148
Sharma V K, Sahai A V, Corder F A. et al .
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance
therapy to prevent further ulcer haemorrhage.
Aliment Pharmacol Ther.
2001;
15 (12)
1939-1947
MissingFormLabel
- 149
Sonnenberg A, Olson C A, Zhang J.
The effect of antibiotic therapy on bleeding from duodenal ulcer.
Am J Gastroenterol.
1999;
94 (4)
950-954
MissingFormLabel
- 150
Blum A L TNO.
Lack of effect of treating Helicobacter pylori infection in patients with nonulcer
dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment
(OCAY) Study Group.
N Engl J Med.
1998;
339 (26)
1875-1881
MissingFormLabel
- 151
Froehlich F, Gonvers J J, Wietlisbach V. et al .
Helicobacter pylori eradication treatment does not benefit patients with nonulcer
dyspepsia.
Am J Gastroenterol.
2001;
96 (8)
2329-2336
MissingFormLabel
- 152
Kamada T, Haruma K, Hata J. et al .
The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic
patients with fundic atrophic gastritis.
Aliment Pharmacol Ther.
2003;
18 (2)
245-252
MissingFormLabel
- 153
Koskenpato J.
Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional
dyspepsia.
The American journal of gastroenterology.
2001;
96 (10)
2866-2872
MissingFormLabel
- 154
Malfertheiner P.
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia.
Alimentary pharmacology & therapeutics.
2003;
18 (6)
615-625
MissingFormLabel
- 155
McColl K.
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with
nonulcer dyspepsia.
The New England journal of medicine.
1998;
339 (26)
1869-1874
MissingFormLabel
- 156
McNamara D, Buckley M, Gilvarry J. et al .
Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: a 5-year
follow-up study.
Helicobacter.
2002;
7 (5)
317-321
MissingFormLabel
- 157
Talley N J VN.
Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia.
The New England journal of medicine.
1999;
341 (15)
1106-1111
MissingFormLabel
- 158
Veldhuyzen v Z, Fedorak R N, Lambert J. et al .
Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple
therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia.
Am J Gastroenterol.
2003;
98 (9)
1963-1969
MissingFormLabel
- 159
Hudson N, Brydon W G, Eastwood M A. et al .
Successful Helicobacter pylori eradication incorporating a one-week antibiotic regimen.
Aliment Pharmacol Ther.
1995;
9 (1)
47-50
MissingFormLabel
- 160
Loo V G, Poirier L, Miller M A. et al .
A Predominantly Clonal Multi-Institutional Outbreak of Clostridium difficile-Associated
Diarrhea with High Morbidity and Mortality.
N Engl J Med.
2005;
353 (23)
2442-2449
MissingFormLabel
- 161
Delaney J A, Dial S, Barkun A. et al .
Antimicrobial drugs and community-acquired Clostridium difficile-associated disease,
UK.
Emerg Infect Dis.
2007;
13 (5)
761-763
MissingFormLabel
- 162
Dial S, Delaney J AC, Barkun A N. et al .
Use of Gastric Acid-Suppressive Agents and the Risk of Community-Acquired Clostridium
difficile-Associated Disease.
JAMA.
2005;
294 (23)
2989-2995
MissingFormLabel
- 163
Drossman D A, Dumitrascu D L.
Rome III: New standard for functional gastrointestinal disorders.
J Gastrointestin Liver Dis.
2006;
15 (3)
237-241
MissingFormLabel
- 164
Chiba N.
Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized
controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia.
Alimentary pharmacology & therapeutics.
2004;
19 (3)
349-358
MissingFormLabel
- 165
Talley N J.
American Gastroenterological Association medical position statement: evaluation of
dyspepsia.
Gastroenterology.
2005;
129 (5)
1753-1755
MissingFormLabel
- 166
Moayyedi P, Soo S, Deeks J. et al .
Eradication of Helicobacter pylori for non-ulcer dyspepsia.
Cochrane Database Syst Rev.
2006;
2
CD002096
MissingFormLabel
- 167
Vakil N.
Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal
reflux disease in Western patients with non-ulcer dyspepsia.
Alimentary pharmacology & therapeutics.
2006;
24 (1)
55-63
MissingFormLabel
- 168
Wu J C, Chan F K, Ching J Y. et al .
Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux
disease: a double blind, placebo controlled, randomised trial.
Gut.
2004;
53 (2)
174-179
MissingFormLabel
- 169
Labenz J, Blum A L, BayerdOrffer E. et al .
Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux
esophagitis.
Gastroenterology.
1997;
112 (5)
1442-1447
MissingFormLabel
- 170
Hamada H, Haruma K, Mihara M. et al .
High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori:
impacts of hiatal hernia and corpus gastritis.
Aliment Pharmacol Ther.
2000;
14 (6)
729-735
MissingFormLabel
- 171
Vakil N, Hahn B, McSorley D.
Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal
ulcer treated for Helicobacter pylori infection.
Aliment Pharmacol Ther.
2000;
14 (1)
45-51
MissingFormLabel
- 172
Laine L, Sugg J.
Effect of Helicobacter pylori eradication on development of erosive esophagitis and
gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind
prospective studies.
Am J Gastroenterol.
2002;
97 (12)
2992-2997
MissingFormLabel
- 173
Vakil N, Talley N J, Stolte M. et al .
Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal
reflux disease in Western patients with non-ulcer dyspepsia.
Aliment Pharmacol Ther.
2006;
24 (1)
55-63
MissingFormLabel
- 174
Pilotto A, Perri F, Leandro G. et al .
Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and
chronic gastritis in the elderly. A randomized, multicenter, eight-month study.
Gerontology.
2006;
52 (2)
99-106
MissingFormLabel
- 175
Kuipers E J, Nelis G F, Klinkenberg-Knol E C. et al .
Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated
with long term omeprazole reverses gastritis without exacerbation of reflux disease:
results of a randomised controlled trial.
Gut.
2004;
53 (1)
12-20
MissingFormLabel
- 176
Malfertheiner P, Dent J, Zeijlon L. et al .
Impact of Helicobacter pylori eradication on heartburn in patients with gastric or
duodenal ulcer disease – results from a randomized trial programme.
Aliment Pharmacol Ther.
2002;
16 (8)
1431-1442
MissingFormLabel
- 177
Moayyedi P, Bardhan C, Young L. et al .
Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal
reflux disease.
Gastroenterology.
2001;
121 (5)
1120-1126
MissingFormLabel
- 178
Schenk B E, Kuipers E J, Nelis G F. et al .
Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy.
Gut.
2000;
46 (5)
615-621
MissingFormLabel
- 179
Lundell L, Miettinen P, Myrvold H E. et al .
Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group.
Gastroenterology.
1999;
117 (2)
319-326
MissingFormLabel
- 180
Franchini M, Cruciani M, Mengoli C. et al .
Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic
purpura: a systematic review and meta-analysis.
J Antimicrob Chemother.
2007;
60 (2)
237-246
MissingFormLabel
- 181
Chen L H, Luo H S.
Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency
anemia patients with H pylori-positive chronic gastristis.
World J Gastroenterol.
2007;
13 (40)
5380-5383
MissingFormLabel
- 182
Tsutsumi Y, Kanamori H, Yamato H. et al .
Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor
monotherapy for idiopathic thrombocytopenic purpura.
Ann Hematol.
2005;
84 (12)
807-811
MissingFormLabel
- 183
Suzuki T, Matsushima M, Masui A. et al .
Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic
purpura – a randomized controlled trial.
Am J Gastroenterol.
2005;
100 (6)
1265-1270
MissingFormLabel
- 184
Emilia G, Longo G, Luppi M. et al .
Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic
purpura.
Blood.
2001;
97 (3)
812-814
MissingFormLabel
- 185
Emilia G, Luppi M, Zucchini P. et al .
Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term
results of bacterium eradication and association with bacterium virulence profiles.
Blood.
2007;
110 (12)
3833-3841
MissingFormLabel
- 186
Yoshimura M, Hirai M, Tanaka N. et al .
Remission of severe anemia persisting for over 20 years after eradication of Helicobacter
pylori in cases of Menetrier’s disease and atrophic gastritis: Helicobacter pylori
as a pathogenic factor in iron-deficiency anemia.
Intern Med.
2003;
42 (10)
971-977
MissingFormLabel
- 187
Kawasaki M, Hizawa K, Aoyagi K. et al .
Menetrier’s disease associated with Helicobacter pylori infection: resolution of enlarged
gastric folds and hypoproteinemia after antibacterial treatment.
Am J Gastroenterol.
1997;
92 (10)
1909-1912
MissingFormLabel
- 188
Yamada M, Sumazaki R, Adachi H. et al .
Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter
pylori.
Eur J Pediatr.
1997;
156 (3)
182-185
MissingFormLabel
- 189
Bayerdörffer E, Ritter M M, Hatz R. et al .
Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter
pylori – is Helicobacter pylori a pathogenic factor in Menetrier’s disease?.
Gut.
1994;
35 (5)
701-704
MissingFormLabel
- 190
Madisch A, Miehlke S, Neuber F. et al .
Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy – a
randomized, double-blind, placebo-controlled multicentre trial.
Aliment Pharmacol Ther.
2006;
23 (4)
473-479
MissingFormLabel
- 191
Chen L H, Luo H S.
Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency
anemia patients with H pylori-positive chronic gastristis.
World J Gastroenterol.
2007;
13 (40)
5380-5383
MissingFormLabel
- 192
Choe Y H, Kim S K, Son B K. et al .
Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency
anemia in preadolescent children and adolescents.
Helicobacter.
1999;
4 (2)
135-139
MissingFormLabel
- 193
Wotherspoon A C, Ortiz-Hidalgo C, Falzon M R. et al .
Helicobacter pylori associated gastritis and primary B-cell gastric lymphoma.
Lancet.
1991;
338
1175-1176
MissingFormLabel
- 194
Stolte M, Eidt S.
Lymphoid follicles in the antral mucosa: immune response to Campylobacter pylori.
J Clin Pathol.
1989;
42
1269-1271
MissingFormLabel
- 195
Stolte M.
H. pylori and gastric MALT lymphoma.
Lancet.
1992;
339
745-746
MissingFormLabel
- 196
Doglioni C, Wotherspoon A C, Moschini A. et al .
High incidence of primary gastric lymphoma in northeastern Italy.
Lancet.
1992;
339
1175-1176
MissingFormLabel
- 197
Zaki M, Schubert M L.
Helicobacter pylori and gastric lymphoma.
Gastroenterology.
1995;
108
610-612
MissingFormLabel
- 198
Hussell T, Isaacson P G, Crabtree J E. et al .
The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated
lymphoid tissue to Helicobacter pylori.
Lancet.
1993;
342
571-574
MissingFormLabel
- 199
Parsonnet J, Freidman G D, Vandersteen D P. et al .
Helicobacter pylori infection and the risk of gastric carcinoma.
N Engl J Med.
1991;
325
1127-1131
MissingFormLabel
- 200
Isaacson P G, Spencer J.
Malignant lymphoma of mucosa-associated lymphoid tissue.
Histopathology.
1987;
11
44-49
MissingFormLabel
- 201
Myhre M J, Isaacson P G.
Primary B-cell gastric lymphoma – a reassessment of its histogenesis.
J Pathol.
1987;
152
1-11
MissingFormLabel
- 202
El-Zimaity H M, Wotherspoon A, Jong de D.
Houston MALT lymphoma Workshop. Interobserver variation in the histopathological assessment
of malt/malt lymphoma: towards a consensus.
Blood Cells Mol Dis.
2005;
34
6-16
MissingFormLabel
- 203
Harris N L, Jaffe E S, Stein H. et al .
A revised European-American classification of lymphoid neoplasms: A proposal from
the international lymphoma study group.
Blood.
1994;
84
1361-1392
MissingFormLabel
- 204
Harris N L, Jaffe E S, Diebold J. et al .
World Health Organization classification of neoplastic diseases of the hematopoietic
and lymphoid tissues: Report of the clinical advisory committee meeting – Airlie House,
Virginia, November 1997.
J Clin Oncol.
1999;
17
3835-3849
MissingFormLabel
- 205
Lymphoma Classification Project .
A clinical evaluation of the international lymphoma study group classification of
non-Hodgkin’s lymphoma.
Blood.
1997;
89
3909-3918
MissingFormLabel
- 206
Musshoff K.
Klinische Stadieneinteilung der nicht-Hodgkin-Lymphome.
Strahlentherapie.
1977;
153
218-222
MissingFormLabel
- 207
Radaszkiewicz T, Dragosics B, Bauer P.
Gastrointestinal malignant lymphomas of the mucosa-associated tissue: Factors relevant
to prognosis.
Gastroenterology.
1992;
102
1628-1638
MissingFormLabel
- 208
Steinbach G, Ford R, Glober G. et al .
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an
uncontrolled trial.
Ann Intern Med.
1999;
131
88-95
MissingFormLabel
- 209
Shimodaira M, Tsukamoto Y, Niwa Y. et al .
A proposed staging system for primary gastric lymphoma.
Cancer.
1994;
73
2709-2715
MissingFormLabel
- 210
Ruskoné-Fourmestraux A, Dragosics B, Morgner A. et al .
Paris staging system for primary gastrointestinal lymphomas.
Gut.
2003;
52
912-913
MissingFormLabel
- 211
Morgner A, Schmelz R, Thiede C. et al .
Therapy of gastric mucosa associated lymphoid tissue lymphoma.
World J Gastroenterol.
2007;
13
3554-3566
MissingFormLabel
- 212
Bayerdorffer E, Neubauer A, Rudolph B. et al .
Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after
cure of Helicobacter pylori infection. MALT Lymphoma Study Group.
Lancet.
1995;
345
1591-1594
MissingFormLabel
- 213
Neubauer A, Thiede C, Morgner A. et al .
Cure of Helicobacter pylori infection and duration of remission of low-grade gastric
mucosa-associated lymphoid tissue lymphoma.
J Natl Cancer Inst.
1997;
89
1350-1355
MissingFormLabel
- 214
Wündisch T, Thiede C, Morgner A. et al .
Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication.
J Clin Oncol.
2005;
23
8018-8024
MissingFormLabel
- 215
Koch P, Probst A, Berdel W E. et al .
Treatment results in localized primary gastric lymphoma: data of patients registered
within the German multicenter study (GIT NHL 02 / 96).
J Clin Oncol.
2005;
23
7050-7059
MissingFormLabel
- 216
Koch P, del Valle F, Berdel W E. et al .
German Multicenter Study Group. Primary gastrointestinal non-Hodgkin’s lymphoma: II.
Combined surgical and conservative or conservative management only in localized gastric
lymphoma – results of the prospective German Multicenter Study GIT NHL 01 / 92.
J Clin Oncol.
2001;
19
3874-3883
MissingFormLabel
- 217
Fischbach W, Dragosics B, Kolve-Goebeler M E. et al .
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian
Gastrointestinal Lymphoma Study Group.
Gastroenterology.
2000;
119
1191-1202
MissingFormLabel
- 218
Raderer M, Wöhrer S, Streubel B. et al .
Assessment of disease dissemination in gastric compared with extragastric mucosa-associated
lymphoid tissue lymphoma using extensive staging: a single-center experience.
J Clin Oncol.
2006;
24
3136-3141
MissingFormLabel
- 219
Flieger D, Keller R, May A. et al .
Capsule endoscopy in gastrointestinal lymphomas.
Endoscopy.
2005;
37
1174-1180
MissingFormLabel
- 220
Morgner A, Miehlke S, Fischbach W. et al .
Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter
pylori infection.
J Clin Oncol.
2001;
19
2041-2048
MissingFormLabel
- 221
Chen L T, Lin J T, Tai J J. et al .
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade
transformed MALT lymphoma.
J Natl Cancer Inst.
2005;
97
1345-1353
MissingFormLabel
- 222
Chen L T, Lin J T, Shyu R Y. et al .
Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade
mucosa-associated lymphoid tissue lymphoma of the stomach.
J Clin Oncol.
2001;
19
4245-4251
MissingFormLabel
- 223
Boot H, Jong de D, Heerde van P. et al .
Role of Helicobacter pylori eradication in high-grade MALT lymphoma.
Lancet.
1995;
346
448-449
MissingFormLabel
- 224
Morgner A, Bayerdörffer E, Neubauer A. et al .
Malignant tumours of the stomach: Gastric MALT lymphoma and Helicobacter pylori. In
Marshall B (ed).
Gastroenterol Clin North Am.
2000;
29
593-607
MissingFormLabel
- 225
Bayerdorffer E, Neubauer A, Rudolph B. et al .
Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after
cure of Helicobacter pylori infection. MALT Lymphoma Study Group.
Lancet.
1995;
345
1591-1594
MissingFormLabel
- 226
Roggero E, Zucca E, Pinotti G. et al .
Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma
of mucosa-associated lymphoid tissue.
Ann Intern Med.
1996;
124
275-276
MissingFormLabel
- 227
Neubauer A, Thiede C, Morgner A. et al .
Cure of Helicobacter pylori infection and duration of remission of low-grade gastric
mucosa-associated lymphoid tissue lymphoma.
J Natl Cancer Inst.
1997;
89
1350-1355
MissingFormLabel
- 228
Steinbach G, Ford R, Glober G. et al .
Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An
uncontrolled trial.
Ann Intern Med.
1999;
131
88-95
MissingFormLabel
- 229
Savio A, Zamboni G, Capelli P. et al .
Relapse of low-grade gastric MALT lymphoma after Helicobacter pylori eradication:
true relapse or persistence? Long-term post-treatment follow-up of a multicenter trial
in the north-east of Italy and evaluation of the diagnostic protocol’s adequacy.
Recent Results Cancer Res.
2000;
156
116-124
MissingFormLabel
- 230
Morgner A, Lehn N, Andersen L P. et al .
Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete
remission after curing the infection.
Gastroenterology.
2000;
118
821-828
MissingFormLabel
- 231
Ruskone-Fourmestraux A, Lavergne A, Aegerter P H. et al .
Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter
pylori treatment.
Gut.
2001;
48
297-303
MissingFormLabel
- 232
Nakamura S, Matsumoto T, Suekane H. et al .
Predictive value of endoscopic ultrasonography for regression of gastric low grade
and high grade MALT lymphomas after eradication of Helicobacter pylori.
Gut.
2001;
48
454-460
MissingFormLabel
- 233
Stolte M, Bayerdorffer E, Morgner A. et al .
Helicobacter and gastric MALT lymphoma.
Gut.
2002;
50 (Suppl 3)
19-24
MissingFormLabel
- 234
Diz-Lois Palomares M T, Souto Ruzo J, Yanez Lopez J A. et al .
Early-stage gastric MALT lymphomas: eradication of H. pylori and outcome.
Rev Esp Enferm Dig.
2002;
94
669-678
MissingFormLabel
- 235
Fischbach W, Goebeler-Kolve M E, Dragosics B. et al .
Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa
associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication
therapy: experience from a large prospective series.
Gut.
2004;
53
34-37
MissingFormLabel
- 236
Wundisch T, Thiede C, Morgner A. et al .
Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication.
J Clin Oncol.
2005;
23
8018-8024
MissingFormLabel
- 237
Wundisch T, Mosch C, Neubauer A. et al .
Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphoma:
Results of a 196-patient series.
Leuk Lymphoma.
2006;
47
2110-2114
MissingFormLabel
- 238
Sackmann M, Morgner A, Rudolph B. et al .
Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted
by endosonographic staging. MALT Lymphoma Study Group.
Gastroenterology.
1997;
113
1087-1090
MissingFormLabel
- 239
Fischbach W, Goebeler-Kolve M, Starostik P. et al .
Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter
pylori.
Lancet.
2002;
360
547-548
MissingFormLabel
- 240
Thiede C, Wundisch T, Alpen B. et al .
German MALT Lymphoma Study Group. Long-term persistence of monoclonal B cells after
cure of Helicobacter pylori infection and complete histologic remission in gastric
mucosa-associated lymphoid tissue B-cell lymphoma.
J Clin Oncol.
2001;
19
1600-1609
MissingFormLabel
- 241
Fischbach W, Goebeler M E, Ruskone-Fourmestraux A. et al .
Most patients with minimal histological residuals of gastric MALT lymphoma after successful
eradication of Helicobacter pylori can be managed safely by a watch and wait strategy:
experience from a large international series.
Gut.
2007;
56
1685-1687
MissingFormLabel
- 242
Ott G, Katzenberger T, Greiner A. et al .
The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration
in low-grade but not high-grade malignant non-Hodgkin’s lymphomas of the mucosa-associated
lymphoid tissue (MALT-)type.
Cancer Res.
1997;
57
3944-3948
MissingFormLabel
- 243
Auer I A, Gascoyne R D, Connors J M. et al .
:t(11;18)(q21;q21) is the most common translocation in MALT lymphomas.
Ann Oncol.
1997;
8
979-985
MissingFormLabel
- 244
Baens M, Maes B, Steyls A. et al .
The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT
type lymphomas without large cell proliferation.
Am J Pathol.
2000;
156
1433-1439
MissingFormLabel
- 245
Liu H, Ruskoné-Fourmestraux A, Lavergne-Slove A. et al .
Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma
to Helicobacter pylori eradication therapy.
Lancet.
2001;
357
39-40
MissingFormLabel
- 246
Liu H, Ye H, Ruskoné-Fourmestraux A. et al .
T(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to
H. pylori eradication.
Gastroenterology.
2002;
122
1286-1294
MissingFormLabel
- 247
Alpen B, Neubauer A, Dierlamm J. et al .
Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT
type responding to eradication of Helicobacter pylori infection.
Blood.
2000;
95
4014-4015
MissingFormLabel
- 248
Nakamura T, Nakamura S, Yonezumi M. et al .
Helicobacter pylori and the t(11;18)(q21;q21) translocation in gastric low-grade B-cell
lymphoma of mucosa-associated lymphoid tissue type.
Jpn J Cancer Res.
2000;
91
301-309
MissingFormLabel
- 249
Ye H, Dogan A, Karran L. et al .
BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in
MALT lymphoma.
Am J Pathol.
2000;
157
1147-1154
MissingFormLabel
- 250
Sugiyama T, Asaka M, Nakamura T. et al .
API2-MALT1 chimeric transcript is a predictive marker for the responsiveness of H.
pylori eradication treatment in low-grade gastric MALT lymphoma.
Gastroenterology.
2001;
120
1884-1885
MissingFormLabel
- 251
Raderer M, Streubel B, Wohrer S. et al .
Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated
lymphoid tissue lymphomas.
Gut.
2006;
55
616-618
MissingFormLabel
- 252
Schechter N R, Yahalom J.
Low-grade MALT lymphoma of the stomach: a review of treatment options.
Int J Radiat Oncol Biol Phys.
2000;
46
1093-1103
MissingFormLabel
- 253
Schechter N R, Portlock C S, Yahalom J.
Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation
alone.
J Clin Oncol.
1998;
16
1916-1921
MissingFormLabel
- 254
Tsang R W, Gospodarowicz M K, Pintilie M. et al .
Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy
has excellent clinical outcome.
J Clin Oncol.
2003;
21
4157-4164
MissingFormLabel
- 255
Tsang R W, Gospodarowicz M K.
Radiation therapy for localized low-grade non-Hodgkin’s lymphomas.
Hematol Oncol.
2005;
23
10-17
MissingFormLabel
- 256
Mittal B, Wasserman T H, Griffith R C.
Non-Hodgkin’s lymphoma of the stomach.
Am J Gastroenterol.
1983;
78
780-787
MissingFormLabel
- 257
Ettinger D S, Carter D.
Gastric carcinoma 16 years after gastric lymphoma irradiation.
Am J Gastroenterol.
1977;
68
485-488
MissingFormLabel
- 258
Shani A, Schutt A J, Weiland L H.
Primary gastric malignant lymphoma followed by gastric adenocarcinoma: report of 4
cases and review of the literature.
Cancer.
1978;
42
2039-2044
MissingFormLabel
- 259
Bartlett D L, Karpeh M S, Filippa D A. et al .
Long-term follow-up after curative surgery for early gastric lymphoma.
Ann Surg.
1996;
223
53-62
MissingFormLabel
- 260
Kodera Jr Y, Yamamura Y, Nakamura S. et al .
The role of radical gastrectomy with systematic lymphadenectomy for the diagnosis
and treatment of primary gastric lymphoma.
Ann Surg.
1998;
227
45-50
MissingFormLabel
- 261
Brands F, Monig S P, Raab M.
Treatment and prognosis of gastric lymphoma.
Eur J Surg.
1997;
163
803-813
MissingFormLabel
- 262
Aviles A, Nambo M J, Neri N. et al .
The role of surgery in primary gastric lymphoma: results of a controlled clinical
trial.
Ann Surg.
2004;
240
44-50
MissingFormLabel
- 263
Aviles A, Nambo M J, Neri N. et al .
Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled
clinical trial.
Med Oncol.
2005;
22
57-62
MissingFormLabel
- 264
ammel P, Haioun C, Chaumette M T. et al .
Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid
tissue lymphoma with prominent gastric expression.
J Clin Oncol.
1995;
13
2524-2529
MissingFormLabel
- 265
Nakamura S, Matsumoto T, Suekane H. et al .
Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated
lymphoid tissue lymphoma with a reference to second-line treatment.
Cancer.
2005;
104
532-540
MissingFormLabel
- 266
Levy M, Copie-Bergman C, Gameiro C. et al .
Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric
lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy.
J Clin Oncol.
2005;
23
5061-5066
MissingFormLabel
- 267
Jäger G, Neumeister P, Brezinschek R. et al .
Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid
tissue type with cladribine: a phase II study.
J Clin Oncol.
2002;
20
3872-3877
MissingFormLabel
- 268
Streubel B, Ye H, Du M Q. et al .
Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with
2CdA in patients with gastric MALT lymphoma.
Oncology.
2004;
66
476-480
MissingFormLabel
- 269
Raderer M, Wohrer S, Bartsch R. et al .
Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid
tissue lymphoma.
J Clin Oncol.
2005;
23
8442-8446
MissingFormLabel
- 270
Conconi A, Martinelli G, Thieblemont C. et al .
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT
type.
Blood.
2003;
102
2741-2745
MissingFormLabel
- 271
Raderer M, Jager G, Brugger S. et al .
Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the
mucosa-associated lymphoid tissue lymphoma.
Oncology.
2003;
65
306-310
MissingFormLabel
- 272
Martinelli G, Laszlo D, Ferreri A J. et al .
Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant
to or not eligible for anti-Helicobacter pylori therapy.
J Clin Oncol.
2005;
23
1979-1983
MissingFormLabel
- 273
Chaudhary N, Ozer H, Huard D. et al .
Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab.
Dig Dis Sci.
2006;
51
775-778
MissingFormLabel
- 274
Salar A, Bellosillo B, Serrano S. et al .
Persistent residual disease in t(11;18)(q21;q21) positive gastric mucosa-associated
lymphoid tissue lymphoma treated with chemotherapy or rituximab.
J Clin Oncol.
2005;
23
7361-7362
MissingFormLabel
- 275
Ferreri A J, Freschi M, Dell’Oro S. et al .
Prognostic significance of the histopathologic recognition of low- and high-grade
components in stage I–II B-cell gastric lymphomas.
Am J Surg Pathol.
2001;
25
95-102
MissingFormLabel
- 276
Ferreri A J, Montalban C.
Primary diffuse large B-cell lymphoma of the stomach.
Crit Rev Oncol Hematol.
2007;
63
65-71
MissingFormLabel
- 277
Coiffier B, Haioun C, Ketterer N. et al .
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing
or refractory aggressive lymphoma: a multicenter phase II study.
Blood.
1998;
92
1927-1932
MissingFormLabel
- 278
Coiffier B, Lepage E, Briere J. et al .
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with
diffuse large-B-cell lymphoma.
N Engl J Med.
2002;
346
235-242
MissingFormLabel
- 279
Watanabe T, Tada M, Nagai H. et al .
Helicobacter pylori infection induces gastric cancer in mongolian gerbils.
Gastroenterology.
1998;
115
642-648
MissingFormLabel
- 280
Ekström A M, Hansson L E, Signorello L B. et al .
Decreasing incidence of both major histologic subtypes of gastric adenocarcinoma –
a population-based study in Sweden.
Br J Cancer.
2000;
83
391-396
MissingFormLabel
- 281
WHO/IARC.
Infection with Helicobacter pylori.
IARC Monogr Eval Carcinog Risks Hum.
1994;
61
177-240
MissingFormLabel
- 282
Stoicov C, Saffari R, Cai X. et al .
Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma:
bacterial and host factors responsible for altered growth signaling.
Gene.
2004;
341
1-17
MissingFormLabel
- 283
Ekström A M, Eriksson M, Hansson L E. et al .
Occupational exposures and risk of gastric cancer in a population-based case-control
study.
Cancer Res.
1999;
59
5932-5937
MissingFormLabel
- 284
Miehlke S, Kirsch C, Agha-Amiri K. et al .
The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma
in Germany.
Int J Cancer.
2000;
87
322-327
MissingFormLabel
- 285
Ekström A M, Serafini M, Nyrén O. et al .
Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the
intestinal and diffuse types: a population-based case-control study in Sweden.
Int J Cancer.
2000;
87
133-140
MissingFormLabel
- 286
González C A, Jakszyn P, Pera G. et al .
Meat intake and risk of stomach and esophageal adenocarcinoma within the European
Prospective Investigation Into Cancer and Nutrition (EPIC).
J Natl Cancer Inst.
2006;
98
345-354
MissingFormLabel
- 287
Sung J J, Lin S R, Ching J Y. et al .
Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective,
randomized study.
Gastroenterology.
2000;
119
7-14
MissingFormLabel
- 288
De Jonge P J, Wolters L M, Steyerberg E W. et al .
Environmental risk factors in the development of adenocarcinoma of the oesophagus
or gastric cardia: a cross-sectional study in a Durch cohort.
Aliment Pharmacol Ther.
2007;
26 (1)
31-39
MissingFormLabel
- 289
Tajima Y, Yamazaki K, Makino R. et al .
Differences in the histological findings, phenotypic marker expressions and genetic
alterations between adenocarcinoma of the gastric cardia and distal stomach.
Br J Cancer.
2007;
96 (1)
631-638
MissingFormLabel
- 290
Crew K D, Neugut A I.
Epidemiology of gastric cancer.
World J Gastroenterol.
2006;
12 (3)
354-362
MissingFormLabel
- 291
Meining A, Stolte M.
Close correlation of intestinal metaplasia and corpus gastritis in patients infected
with Helicobacter pylori.
Z Gastroenterol.
2002;
40
557-560
MissingFormLabel
- 292
Matsuhisa T, Matsukura N, Yamada N.
Topography of chronic active gastritis in Helicobacter pylori-positive Asian populations:
age-, gender-, and endoscopic diagnosis-matched study.
J Gastroenterol.
2004;
39
324-328
MissingFormLabel
- 293
Imagawa S, Yoshihara M, Ito M. et al .
Evaluation of Gastric Cancer Risk Using Topography of Histological Gastritis: A Large-scaled
Cross-sectional Study.
Dig Dis Sci.
2007;
13
Epub ahead of print
MissingFormLabel
- 294
Miehlke S, Hackelsberger A, Meining A. et al .
Severe expression of corpus gastritis is characteristic in gastric cancer patients
infected with Helicobacter pylori.
Br J Cancer.
1998;
78
263-266
MissingFormLabel
- 295
Meining A G, Bayerdörffer E, Stolte M.
Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric
carcinoma patients.
Eur J Gastroenterol Hepatol.
1999;
11
717-720
MissingFormLabel
- 296
Meining A, Riedl B, Stolte M.
Features of gastritis predisposing to gastric adenoma and early gastric cancer.
J Clin Pathol.
2002;
55
770-773
MissingFormLabel
- 297
Oberhuber G, Stolte M.
Gastric polyps: an update of their pathology and biological significance.
Virchows Arch.
2000;
437
581-590
MissingFormLabel
- 298
Malfertheiner P, Megraud F, O’Morain C. et al .
Current concepts in the management of Helicobacter pylori infection: the Maastricht
III Consensus Report.
Gut.
2007;
56
772-781
MissingFormLabel
- 299
Wong B C, Lam S K, Wong W M. et al .
: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region
of China: a randomized controlled trial.
JAMA.
2004;
291
187-194
MissingFormLabel
- 300
Forman D, Graham D Y.
Review article: impact of Helicobacter pylori on society-role for a strategy of ‘search
and eradicate’.
Aliment Pharmacol Ther.
2004;
19 (Suppl 1)
17-21
MissingFormLabel
- 301
Fischbach L, Evans E L.
Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple
and quadruple first-line therapies for Helicobacter pylori.
Aliment Pharmacol Ther.
2007;
26
343-357
MissingFormLabel
- 302
Janssen M J, Laheij R J. et al .
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Neth J Med.
2004;
62
192-196
MissingFormLabel
- 303
Laheij R J, Rossum L G. et al .
Evaluation of treatment regimens to cure Helicobacter pylori infection – a meta-analysis.
Aliment Pharmacol Ther.
1999;
13 (7)
857-864
MissingFormLabel
- 304
Megraud F.
H pylori antibiotic resistance: prevalence, importance, and advances in testing.
Gut.
2004;
53
1374-1384
MissingFormLabel
- 305
Wouden E J, Thijs J C. et al .
The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing
anti-Helicobacter pylori regimens: a meta-analysis.
Am J Gastroenterol.
1999;
94
1751-1759
MissingFormLabel
- 306
Fuccio van der L, Minardi M E. et al .
Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for
Helicobacter pylori eradication.
Ann Intern Med.
2007;
147
553-562
MissingFormLabel
- 307
Furuta T, Shirai N. et al .
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Drug Metab Pharmacokinet.
2005;
20
153-167
MissingFormLabel
- 308
Gisbert J P, Khorrami S. et al .
Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication
therapy for the prevention of recurrent bleeding from peptic ulcer.
Aliment Pharmacol Ther.
2004;
19
617-629
MissingFormLabel
- 309
Graham D Y.
Therapy of Helicobacter pylori: current status and issues.
Gastroenterology.
2000;
118 (Suppl 1)
S2-S8
MissingFormLabel
- 310
Huang J Q, Zheng G F. et al .
Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication
treatments from those with peptic ulcer disease? A systematic review.
World J Gastroenterol.
2005;
11
2726-2732
MissingFormLabel
- 311
Klotz U, Schwab M. et al .
CYP2C19 polymorphism and proton pump inhibitors.
Basic Clin Pharmacol Toxicol.
2004;
95
2-8
MissingFormLabel
- 312
Lind T, Megraud F. et al .
The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week
triple therapies.
Gastroenterology.
1999;
116
248-253
MissingFormLabel
- 313
Malfertheiner P, Bayerdorffer E. et al .
The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter
pylori infection in patients with gastric ulcer.
Aliment Pharmacol Ther.
1999;
13
703-712
MissingFormLabel
- 314
Malfertheiner P, Peitz U. et al .
What constitutes failure for Helicobacter pylori eradication therapy?.
Can J Gastroenterol.
2003;
17 (Suppl B)
53B-57B
MissingFormLabel
- 315
Malfertheiner P, Megraud F. et al .
Current concepts in the management of Helicobacter pylori infection: the Maastricht
III Consensus Report.
Gut.
2007;
56
772-781
MissingFormLabel
- 316
Moayyedi P, Soo S. et al .
Eradication of Helicobacter pylori for non-ulcer dyspepsia.
Cochrane Database Syst Rev.
2006;
2
CD002096
MissingFormLabel
- 317
Morgner A, Labenz J. et al .
Effective regimens for the treatment of Helicobacter pylori infection.
Expert Opin Investig Drugs.
2006;
15
995-1016
MissingFormLabel
- 318
Padol S, Yuan Y. et al .
The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple
first-line PPI therapies: a meta-analysis.
Am J Gastroenterol.
2006;
101
1467-1475
MissingFormLabel
- 319
Treiber G, Malfertheiner P. et al .
Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic.
Expert Opin Pharmacother.
2007;
8
329-350
MissingFormLabel
- 320
Vakil N, Megraud F.
Eradication therapy for Helicobacter pylori.
Gastroenterology.
2007;
133
985-1001
MissingFormLabel
- 321
Hopkins R J.
Current FDA-approved treatments for Helicobacter pylori and the FDA approval process.
Gastroenterology.
1997;
113
S126-S130
MissingFormLabel
- 322
Graham D Y, Lu H. et al .
A report card to grade Helicobacter pylori therapy.
Helicobacter.
2007;
12
275-278
MissingFormLabel
- 323
Calvet X, Garcia N. et al .
A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin
and either metronidazole or amoxycillin for treating Helicobacter pylori infection.
Aliment Pharmacol Ther.
2000;
14
603-609
MissingFormLabel
- 324
Chiba N, Rao B V. et al .
Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori.
Am J Gastroenterol.
1992;
87
1716-1727
MissingFormLabel
- 325
Gisbert J P, Khorrami S. et al .
Meta-analysis: proton pump inhibitors vs. H 2-receptor antagonists – their efficacy
with antibiotics in Helicobacter pylori eradication.
Aliment Pharmacol Ther.
2003;
18
757-766
MissingFormLabel
- 326
Graham D Y, Hammoud F. et al .
Meta-analysis: proton pump inhibitor or H 2-receptor antagonist for Helicobacter pylori
eradication.
Aliment Pharmacol Ther.
2003;
17
1229-1236
MissingFormLabel
- 327
Huang J, Hunt R H.
The importance of clarithromycin dose in the management of Helicobacter pylori infection:
a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and
amoxycillin or metronidazole.
Aliment Pharmacol Ther.
1999;
13
719-729
MissingFormLabel
- 328
Treiber G.
The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness
analysis.
Am J Gastroenterol.
1996;
91
246-257
MissingFormLabel
- 329
Treiber G.
Treating H. pylori shorter than one week – a real future perspective?.
Z Gastroenterol.
2000;
38
807-812
MissingFormLabel
- 330
Unge P.
Antimicrobial treatment of H. pylori infection – a pooled efficacy analysis of eradication
therapies.
Eur J Surg Suppl.
1998;
582
16-26
MissingFormLabel
- 331
Ford A C, Delaney B C. et al .
Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic
review and economic analysis.
Am J Gastroenterol.
2004;
99
1833-1855
MissingFormLabel
- 332
Gene E, Calvet X. et al .
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.
Aliment Pharmacol Ther.
2003;
17
1137-1143
MissingFormLabel
- 333
Kist M.
Helicobacter pylori: primary antimicrobial resistance and first-line treatment strategies.
Euro Surveill.
2007;
12
E1-E2
MissingFormLabel
- 334
Taylor J L, Zagari M. et al .
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori.
Arch Intern Med.
1997;
157
87-97
MissingFormLabel
- 335
Wolle K, Leodolter A. et al .
Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance
from 1995 to 2000.
J Med Microbiol.
2002;
51
705-709
MissingFormLabel
- 336
Fischbach L A, Zanten van S. et al .
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter
pylori quadruple therapies.
Aliment Pharmacol Ther.
2004;
20
1071-1082
MissingFormLabel
- 337
Neville P M, Everett S. et al .
The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.
Aliment Pharmacol Ther.
1999;
13
497-501
MissingFormLabel
- 338
Treiber G, Wittig J. et al .
Clinical outcome and influencing factors of a new short-term quadruple therapy for
Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Arch Intern Med.
2002;
162
153-160
MissingFormLabel
- 339
Vaira D, Zullo A. et al .
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication:
a randomized trial.
Ann Intern Med.
2007;
146
556-563
MissingFormLabel
- 340
Zullo A, De Francesco V. et al .
The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data
analysis.
Gut.
2007;
56
1353-1357
MissingFormLabel
- 341
Treiber G, Malfertheiner P. et al .
Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic.
Expert Opin Pharmacother.
2007;
8
329-350
MissingFormLabel
- 342
Janssen M J, Laheij R J. et al .
Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter
pylori eradication.
Aliment Pharmacol Ther.
2005;
21
341-345
MissingFormLabel
- 343
Klotz U, Schwab M. et al .
CYP2C19 polymorphism and proton pump inhibitors.
Basic Clin Pharmacol Toxicol.
2004;
95
2-8
MissingFormLabel
- 344
Bortoli de N, Leonardi G. et al .
Helicobacter pylori eradication: a randomized prospective study of triple therapy
versus triple therapy plus lactoferrin and probiotics.
Am J Gastroenterol.
2007;
102
951-956
MissingFormLabel
- 345
Gotteland M, Brunser O. et al .
Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter
pylori?.
Aliment Pharmacol Ther.
2006;
23
1077-1086
MissingFormLabel
- 346
Tong J L, Ran Z H. et al .
Meta-analysis: the effect of supplementation with probiotics on eradication rates
and adverse events during Helicobacter pylori eradication therapy.
Aliment Pharmacol Ther.
2007;
25
55-68
MissingFormLabel
- 347
Leodolter A, Kulig M. et al .
A meta-analysis comparing eradication, healing and relapse rates in patients with
Helicobacter pylori-associated gastric or duodenal ulcer.
Aliment Pharmacol Ther.
2001;
15
1949-1958
MissingFormLabel
- 348
Treiber G, Lambert J R.
The impact of Helicobacter pylori eradication on peptic ulcer healing.
Am J Gastroenterol.
1998;
93
1080-1084
MissingFormLabel
- 349
Adamek R J, Opferkuch W. et al .
Cure of Helicobacter pylori infection: role of duration of treatment with omeprazole
and amoxicillin.
Am J Gastroenterol.
1996;
91
98-100
MissingFormLabel
- 350
Wouden E J, Thijs J C. et al .
The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing
anti-Helicobacter pylori regimens: a meta-analysis.
Am J Gastroenterol.
1999;
94
1751-1759
MissingFormLabel
- 351
Gisbert J P, Pajares J M.
Helicobacter pylori „rescue” therapy after failure of two eradication treatments.
Helicobacter.
2005;
10
363-372
MissingFormLabel
- 352
Gisbert J P, Morena van der F.
Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter
pylori treatment failure.
Aliment Pharmacol Ther.
2006;
23
35-44
MissingFormLabel
- 353
Miehlke S, Schneider-Brachert W, Kirsch C. et al .
One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin
for eradication of persistent Helicobacter pylori resistant to both metronidazole
and clarithromycin.
Helicobacter.
2008;
13
69-74
MissingFormLabel
- 354
Yuan Y, Thabane L. et al .
Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure: how
strong is the evidence?.
Aliment Pharmacol Ther.
2006;
23
1283-1285; author reply 1285 – 1286
MissingFormLabel
- 355
Koletzko S, Feydt-Schmidt A.
Infants differ from teenagers: use of non-invasive tests for detection of Helicobacter
pylori infection in children.
Eur J Gastroenterol Hepatol.
2001;
13
1047-1052
MissingFormLabel
- 356
Jones N, Fallone C, Flook N. et al .
Consensus Conference: Update on the Management of Helicobacter pylori – An evidence-based
evaluation of Helicobacter pylori infection and clinical sequelae in children and
adolescents.
Can J Gastroenterol.
2005;
19
398-408
MissingFormLabel
- 357
Drumm B, Koletzko S, Oderda G.
Helicobacter pylori infection in children: A consensus statement.
J Pediatr Gastroenterol Nutr.
2000;
30
207-213
MissingFormLabel
- 358
Koletzko S, Richy F, Bontems P. et al .
Prospective multicenter study on antibiotic resistance of Helicbacter pylori strains
obtained from children living in Europe.
Gut.
2006;
55
1711-1716
MissingFormLabel
- 359
Kurugoglu S, Mihmanli I, Celkan T. et al .
Radiological features in paediatric primary gastric MALT lymphoma and association
with Helicobacter pylori.
Pediatr Radiol.
2002;
32
82-87
MissingFormLabel
- 360
Lionetti E, Miniello V L, Castellaneta S P. et al .
Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori
treatment in children: a randomized placebo controlled trial.
Aliment Pharmacol Ther.
2006;
24
1461-1468
MissingFormLabel
- 361
Khurana R, Fischbach L, Chiba N. et al .
Meta-analysis: Helicobacter pylori eradication treatment efficacy in children.
Aliment Pharmacol Ther.
2007;
25
523-536
MissingFormLabel
- 362
Oderda G, Shcherbakov P, Bontems P. et al .
Results from the pediatric European register for treatment of Helicobacter pylori
(PERTH).
Helicobacter.
2007;
12
150-156
MissingFormLabel
- 363
Feydt-Schmidt A, Kindermann A, Konstantopoulos N. et al .
Reinfection rate in children after successful Helicobacter pylori eradication.
Eur J Gastroenterol Hepatol.
2002;
14
1119-1123
MissingFormLabel
- 364
Rowland M, Kumar D, Daly L. et al .
Low rates of Helicobacter pylori reinfection in children.
Gastroenterology.
1999;
117
336-341
MissingFormLabel
- 365
Rasquin A, Di Lorenzo C, Forbes D. et al .
Childhood functional gastrointestinal disorders: child/adolescent.
Gastroenterology.
2006;
130
1527-1537
MissingFormLabel
- 366
Kohli R, Li B UK.
Differential diagnosis of recurrent abdominal pain: new considerations.
Pediatric Annals.
2004;
33
113-122
MissingFormLabel
- 367
Chitkara D K, Rawat D J, Talley N J.
The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic
review.
Am J Gastroenterol.
2005;
100
1868-1875
MissingFormLabel
- 368
Hyams J S, Burke G, Davis P M. et al .
Abdominal pain and irritable bowel syndrome in adolescents: a community-based study.
J Pediatr.
1996;
129
220-226
MissingFormLabel
- 369
Apley J, Naish N.
Recurrent abdominal pains: A field survey of 1,000 school children.
Arch Dis Child.
1958;
33
165-170
MissingFormLabel
- 370
Tindberg Y, Nyren O, Blennow M. et al .
Helicobacter pylori infection and abdominal symptoms among Swedish school children.
J Pediatr Gastroenterol Nutr.
2005;
41
33-38
MissingFormLabel
- 371
Falsafi T, Valizadeh N, Sepehr S. et al .
Application of a stool antigen test to evaluate the incidence of Helicobacter pylori
infection in children and adolescents from Tehran, Iran.
Clin Diagn Lab Immunol.
2005;
12
1094-1097
MissingFormLabel
- 372
Leandro Liberato S V, Hernandez Galindo M, Torroba Alvarez L. et al .
Helicobacter pylori infection in the child population in Spain: prevalence, related
factors and influence on growth.
Ann Pediatr.
2005;
63
489-494
MissingFormLabel
- 373
Bode G, Brenner H, Adler G. et al .
Recurrent abdominal pain in children: evidence from a population-based study that
social and familial factors play a major role but not Helicobacter pylori infection.
J Psychosom Res.
2003;
54
417-421
MissingFormLabel
- 374
Bode G, Rothenbacher D, Brenner H. et al .
Helicobacter pylori and abdominal symptoms: a population-based study among preschool
children in southern Germany.
Pediatrics.
1998;
101
634-637
MissingFormLabel
- 375
Macarthur C, Saunders N, Feldman W.
Helicobacter pylori, gastroduodenal disease, and recurrent abdominal pain in children.
JAMA.
1995;
273
729-734
MissingFormLabel
- 376
Macarthur C, Saunders N, Feldman W. et al .
Helicobacter pylori and childhood recurrent abdominal pain: community based case-control
study.
BMJ.
1999;
319
822-823
MissingFormLabel
- 377
Kalach N, Mention K, Guimber D. et al .
Helicobacter pylori infection is not associated with specific symptoms in nonulcer-dyspeptic
children.
Pediatrics.
2005;
115
17-21
MissingFormLabel
- 378
Das B K, Kakkar S, Dixit V K. et al .
Helicobacter pylori infection and recurrent abdominal pain in children.
J Trop Pediatr.
2003;
49
250-252
MissingFormLabel
- 379
Frank F, Stricker T, Stallmach T. et al .
Helicobacter pylori infection in recurrent abdominal pain.
J Pediatr Gastroenterol Nutr.
2000;
31
424-427
MissingFormLabel
- 380
Wewer V, Andersen L P, Paerregaard A. et al .
Treatment of Helicobacter pylori in children with recurrent abdominal pain.
Helicobacter.
2001;
6
244-248
MissingFormLabel
- 381
Alfven G.
One hundred cases of recurrent abdominal pain in children: diagnostic procedures and
criteria for a psychosomatic diagnosis.
Acta Paediatr.
2003;
92
43-49
MissingFormLabel
- 382
Ukarapol N, Lertprasertsuk N, Wongsawasdi L.
Recurrent abdominal pain in children: the utility of upper endoscopy and histopathology.
Singapore Med J.
2004;
45
121-124
MissingFormLabel
- 383
Ashorn M, Rago T, Kokkonen J. et al .
Symptomatic response to Helicobacter pylori eradication in children with recurrent
abdominal pain: double blind randomized placebo-controlled trial.
J Clin Gastroenterol.
2004;
38
646-650
MissingFormLabel
- 384
Rafeey M, Jafari-Rouhi A H, Gassemi B A. et al .
Relationship between endoscopic nodular gastritis and Helicobacter pylori infection
in children.
Indian J Gastroenterol.
2004;
23
138-139
MissingFormLabel
- 385
Bahu M G, da Silveira T R, Maguilnick I. et al .
Endoscopic nodular gastritis: an endoscopic indicator of high-grade bacterial colonization
and severe gastritis in children with Helicobacter pylori.
J Pediatr Gastroenterol Nutr.
2003;
36
217-222
MissingFormLabel
- 386
Luzza F, Pensabene L, Imeneo M. et al .
Antral nodularity and positive CagA serology are distinct and relevant markers of
severe gastric inflammation in children with Helicobacter pylori infection.
Helicobacter.
2002;
7
46-52
MissingFormLabel
- 387
Ganga Z P, Michaud L, Vincent P. et al .
Natural outcome of Helicobacter pylori infection in asymptomatic children: a two-year
follow-up study.
Pediatrics.
1999;
104
216-221
MissingFormLabel
- 388
Barabino A, Dufour C, Marino C E. et al .
Unexplained refractory iron-deficiency anemia associated with Helicobacter pylori
gastric infection in children: Further clinical evidence.
J Pediatr Gastroenterol Nutr.
1999;
28 (1)
116-119
MissingFormLabel
- 389
Ashorn M, Ruuska T, Makipernaa A.
Helicobacter pylori and iron deficiency anaemia in children.
Scand J Gastroenterol.
2001;
36
701-705
MissingFormLabel
- 390
Choe Y H, Lee J E, Kim S K.
Effect of Helicobacter pylori eradication on sideropenic refractory anaemia in adolescent
girls with Helicobacter pylori infection.
Acta Paediatr.
2000;
89
154-157
MissingFormLabel
- 391
Choe Y H, Kim S K, Son B K. et al .
Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency
anemia in preadolescent children and adolescents.
Helicobacter.
1999;
4
135-139
MissingFormLabel
- 392
Emin-Kurekci A, Avni-Atay A, Umit-Sarici S. et al .
Is there a relationship between childhood Helicobacter pylori infection and iron deficiency
anemia?.
J Trop Pediatr.
2005;
51
166-169
MissingFormLabel
- 393
Gessner B D, Baggett H C, Muth P T. et al .
A controlled, household-randomized, open-label trial of the effect that treatment
of Helicobacter pylori infection has on iron deficiency in children in rural Alaska.
J Infect Dis.
2006;
193
537-546
MissingFormLabel
- 394
Kerr J G, Al-Khattaf A, Barson A J. et al .
An association between sudden infant death syndrome (SIDS) and Helicobacter pylori
infection.
Arch Dis Child.
2000;
83
429-434
MissingFormLabel
- 395
Karlidag T, Bulut Y, Keles E. et al .
Detection of Helicobacter pylori in children with otitis media with effusion: a preliminary
report.
Laryngoscope.
2005;
115
1262-1265
MissingFormLabel
- 396
Koletzko S, Konstantopoulos N, Lehn N. et al .
Control your controls and conclusions.
Arch Dis Child.
2001;
84
525
MissingFormLabel
- 397
Bitar M, Mahfouz R, Soweid A. et al .
Does Helicobacter pylori colonize the nasopharynx of children and contribute to their
middle ear disease?.
Acta Otolaryngol.
2006;
126
154-159
MissingFormLabel
- 398
Vaira D, Menegatti M, Salardi S. et al .
Helicobacter pylori and diminished growth in children: is it simply a marker of deprivation?.
Ital J Gastroenterol Hepatol.
1998;
30
129-133
MissingFormLabel
- 399
Richter T, Richter T, List S. et al .
Five- to 7-year-old children with Helicobacter pylori infection are smaller than Helicobacter-negative
children: a cross-sectional population-based study of 3,315 children.
J Pediatr Gastroenterol Nutr.
2001;
33
472-475
MissingFormLabel
- 400
Oderda G, Palli D, Saieva C. et al .
Short stature and Helicobacter pylori infection in italian children: prospective multicentre
hospital based case-control study. The Italian Study Group on Short Stature and H
pylori.
BMJ.
1998;
317
514-515
MissingFormLabel
- 401
Pitkaranta A, Kolho K L, Rautelin H.
Helicobacter pylori in children who are prone to upper respiratory tract infections.
Arch Otolaryngol Head Neck Surg.
2005;
131
256-258
MissingFormLabel
- 402
Kindermann A, Demmelmair H, Koletzko B. et al .
Influence of age on 13C-urea breath test results in children.
J Pediatr Gastroenterol Nutr.
2000;
30
85-91
MissingFormLabel
- 403
Cadranel S, Corvaglia L, Bontems P. et al .
Detection of Helicobacter pylori infection in children with standardized and simplified
13C-urea breath test.
J Pediatr Gastroenterol Nutr.
1998;
27
275-280
MissingFormLabel
- 404
Megraud F.
Comparison of non-invasive tests to detect Helicobacter pylori infection in children
and adolescents: results of a multicenter European study.
J Pediatr.
2005;
146
198-203
MissingFormLabel
- 405
Kato S, Ozawa K, Konno M. et al .
Diagnostic accuracy of the 13C-urea breath test for childhood Helicobacter pylori
infection: a multicenter Japanese study.
Am J Gastroenterol.
2002;
97
1668-1673
MissingFormLabel
- 406
Herold R, Becker M.
13C-urea breath test threshold calculation and evaluation for the detection of Helicobacter
pylori infection in children.
BMC Gastroenterol.
2002;
2
12
MissingFormLabel
- 407
Koletzko S.
Noninvasive diagnostic tests for Helicobacter pylori infection in children.
Can J Gastroenterol.
2005;
19
433-439
MissingFormLabel
- 408
Imrie C, Rowland M, Bourke B. et al .
Limitations to carbon 13-labeled urea breath testing for Helicobacter pylori in infants.
J Pediatr.
2001;
139
734-737
MissingFormLabel
- 409
Klein P D, Malaty H M, Czinn S J. et al .
Normalizing results of 13C-urea breath testing for CO 2 production rates in children.
J Pediatr Gastroenterol Nutr.
1999;
29
297-301
MissingFormLabel
- 410
Graham D Y, Opekun A R, Jogi M. et al .
False negative urea breath tests with H 2-receptor antagonists: interactions between
Helicobacter pylori density and pH.
Helicobacter.
2004;
9
17-27
MissingFormLabel
- 411
Graham D Y, Opekun A R, Hammoud F. et al .
Studies regarding the mechanism of false negative urea breath tests with proton pump
inhibitors.
Am J Gastroenterol.
2003;
98
1005-1009
MissingFormLabel
- 412
Megraud F.
Non-invasive tests to detect Helicobacter pylori infection in children and adolescents:
results of a multicentric European study.
J Pediatr.
2005;
146
198-203
MissingFormLabel
- 413
Koletzko S, Konstantopoulos N, Bosman D. et al .
Evaluation of a novel monoclonal enzyme immunoassay for detection of Helicobacter
pylori antigen in stool from children.
Gut.
2003;
52
804-806
MissingFormLabel
- 414
Schwarzer A, Lottspeich C, Russmann H. et al .
Evaluation of a novel rapid one-step monoclonal chromatographic immunoassay for detection
of Helicobacter pylori in stool from children.
Eur J Clin Microbiol Infect Dis.
2007;
26
475-480
MissingFormLabel
- 415
Hino B, Eliakim R, Levine A. et al .
Comparison of invasive and non-invasive tests diagnosis and monitoring of Helicobacter
pylori infection in children.
J Pediatr Gastroenterol Nutr.
2004;
39
519-523
MissingFormLabel
- 416
Gisbert J P, Morena de la F, Abraira V.
Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection:
a systematic review and meta-analysis.
Am J Gastroenterol.
2006;
101
1921-1930
MissingFormLabel
- 417
Konstantopoulos N, Russmann H, Tasch C. et al .
Evaluation of the Helicobacter pylori stool antigen test (HpSA) for detection of Helicobacter
pylori infection in children.
Am J Gastroenterol.
2001;
96
677-683
MissingFormLabel
- 418
Makristathis A, Barousch W, Pasching E. et al .
Two enzyme immunoassays and PCR for detection of Helicobacter pylori in stool specimens
from Pediatric Patients before and after eradication therapy.
J Clin Microbiol.
2000;
38
3710-3714
MissingFormLabel
- 419
Antos D, Crone J, Konstantopoulos N. et al .
Evaluation of a novel rapid one-step immunochromatographic assay for detection of
monoclonal Helicobacter pylori antigen in stool samples from children.
J Clin Microbiol.
2005;
43
2598-2601
MissingFormLabel
- 420
Lottspeich C, Schwarzer A, Panthel K. et al .
Evaluation of the novel Helicobacter pylori ClariRes real-time PCR assay for detection
and clarithromycin susceptibility testing of H. pylori in stool specimens from symptomatic
children.
J Clin Microbiol.
2007;
45
1718-1722
MissingFormLabel
- 421
Oliveira A MR, Rocha G A, Queiroz D M. et al .
Evaluation of enzyme-linked immunosorbent assay for the diagnosis of Helicobacter
pylori infection in children from different age groups with and without duodenal ulcer
(see comments).
J Pediatr Gastroenterol Nutr.
1999;
28
157-161
MissingFormLabel
- 422
Kindermann A, Konstantopoulos N, Lehn N. et al .
Evaluation of two commercial enzyme immunoassays, testing immunoglobulin G (IgG) and
IgA responses, for diagnosis of Helicobacter pylori infection in children.
J Clin Microbiol.
2001;
39
3591-3596
MissingFormLabel
- 423
Rocha G A, Oliveira A M, Queiroz D M. et al .
Immunoblot analysis of humoral immune response to Helicobacter pylori in children
with and without duodenal ulcer.
J Clin Microbiol.
2000;
38
1777-1781
MissingFormLabel
- 424
Ni Y H, Lin J T, Huang S F. et al .
Accurate diagnosis of Helicobacter pylori infection by stool antigen test and 6 other
currently available tests in children (see comments).
J Pediatr.
2000;
136
823-827
MissingFormLabel
- 425
Raymond J, Sauvestre C, Kalach N. et al .
Immunoblotting and serology for diagnosis of Helicobacter pylori infection in children.
Pediatr Infect Dis J.
2000;
19
118-121
MissingFormLabel
- 426
Raymond J, Sauvestre C, Kalach N. et al .
Evaluation of a new serologic test for diagnosis of Helicobacter pylori infection
in children.
Eur J Clin Microbiol Infect Dis.
1999;
18
192-198
MissingFormLabel
- 427
Kalach N, Benhamou P H, Campeotto F. et al .
Clarithromycin resistance and eradication of Helicobacter pylori in children.
Antimicrob Agents Chemother.
2001;
45
2134-2135
MissingFormLabel
- 428
Wolle K, Leodolter A, Malfertheiner P. et al .
Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance
from 1995 to 2000.
J Med Microbiol.
2002;
51
705-709
MissingFormLabel
- 429
Pohle T, Stoll R, Kirchner T. et al .
Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole
– an open pilot study.
Aliment Pharmacol Ther.
1998;
12
1273-1278
MissingFormLabel
- 430
Megraud F, Lehn N, Lind T. et al .
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter
trial: the MACH 2 study.
Antimicrob Agents Chemother.
1999;
43
2747-2752
MissingFormLabel
- 431
Arenz T, Antos D, Russmann H. et al .
Esomeprazole-based 1-week triple therapy directed by susceptibility testing for eradication
of Helicobacter pylori infection in children.
J Pediatr Gastroenterol Nutr.
2006;
43
180-184
MissingFormLabel
- 432
Feydt-Schmidt A, Russmann H, Lehn N. et al .
Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible
and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from
children.
Aliment Pharmacol Ther.
2002;
16
2073-2079
MissingFormLabel
- 433
Rüssmann H, Feydt-Schmidt A, Adler K. et al .
Detection of Helicobacter pylori in paraffin-embedded and in shock-frozen gastric
biopsy samples by fluorescent in situ hybridization.
J Clin Microbiol.
2003;
41
813-815
MissingFormLabel
- 434
Drumm B, Rhoads J M, Stringer D A. et al .
Peptic ulcer disease in children: etiology, clinical findings, and clinical course.
Pediatrics.
1988;
82
410-414
MissingFormLabel
- 435
Kivi M, Tindberg Y, Sorberg M. et al .
Concordance of Helicobacter pylori strains within families.
J Clin Microbiol.
2003;
41
5604-5608
MissingFormLabel
- 436
Crone J, Granditsch G, Huber W D. et al .
Helicobacter pylori in children and adolescents: increase of primary clarithromycin
resistance, 1997 – 2000.
J Pediatr Gastroenterol Nutr.
2003;
36
368-371
MissingFormLabel
- 437
Francavilla R, Lionetti E, Castellaneta S P. et al .
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication
in children: a randomized trial.
Gastroenterology.
2005;
129
1414-1419
MissingFormLabel
- 438
Zullo A, Francesco, V. et al .
The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data
analysis.
Gut.
2007;
56
1353-1357
MissingFormLabel
- 439
Miehlke S, Kirsch C, Schneider-Brachert W. et al .
A prospective, randomized study of quadruple therapy and high-dose dual therapy for
treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Helicobacter.
2003;
8
310-319
MissingFormLabel
- 440
Gatta L, Vakil N, Ricci C. et al .
Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and
stool test for Helicobacter pylori infection.
Am J Gastroenterol.
2004;
99
823-829
MissingFormLabel
- 441
Miehlke S, Bayerdorffer E, Lehn N. et al .
Recurrence of duodenal ulcers during five years of follow-up after cure of Helicobacter
pylori infection.
Eur J Gastroenterol Hepatol.
1995;
7
975-978
MissingFormLabel
- 442
Kalach N, Bergeret M, Benhamou P H. et al .
High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori
strains in children.
J Clin Microbiol.
2001;
39
394-397
MissingFormLabel
- 443
Hansen J M, Hallas J, Lauritsen J M. et al .
Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis
for clinical decision-making.
Scand J Gastroenterol.
1996;
31
126-130
MissingFormLabel
- 444
Hernandez-Diaz S, Rodriguez L A.
Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal
tract bleeding/perforation: an overview of epidemiologic studies published in the
1990 s.
Arch Intern Med.
2000;
160
2093-2099
MissingFormLabel
- 445
Hawkey C J, Weinstein W M, Smalley W. et al .
Effect of Risk Factors on Complicated and Uncomplicated Ulcers in the TARGET Lumiracoxib
Outcomes Study.
Gastroenterology.
2007;
133
57-64
MissingFormLabel
- 446
Henry D, Lim L L, Garcia Rodriguez L A. et al .
Variability in risk of gastrointestinal complications with individual non-steroidal
anti-inflammatory drugs: results of a collaborative meta-analysis.
BMJ.
1996;
312
1563-1566
MissingFormLabel
- 447
Weil J, Langman M J, Wainwright P. et al .
Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal
anti-inflammatory drugs.
Gut.
2000;
46
27-31
MissingFormLabel
- 448
Scheiman J M, Yeomans N D, Talley N J. et al .
Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs
and COX-2 inhibitors.
Am J Gastroenterol.
2006;
101
701-710
MissingFormLabel
- 449
Miyake K, Ueki N, Suzuki K. et al .
Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese
patients with rheumatoid arthritis: the current situation and a prospective controlled-study
of the preventive effects of lansoprazole or famotidine.
Aliment Pharmacol Ther.
2005;
21 (Suppl 2)
67-72
MissingFormLabel
- 450
Stupnicki T, Dietrich K, Gonzalez-Carro P. et al .
Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention
of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients.
Digestion.
2003;
68
198-208
MissingFormLabel
- 451
Labenz J, Blum A L, Bolten W W. et al .
Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or
triple therapy in Helicobacter pylori positive patients: a randomised, double blind,
placebo controlled, clinical trial.
Gut.
2002;
51
329-335
MissingFormLabel
- 452
Graham D Y, Agrawal N M, Campbell D R. et al .
Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results
of a double-blind, randomized, multicenter, active- and placebo-controlled study of
misoprostol vs lansoprazole.
Arch Intern Med.
2002;
162
169-175
MissingFormLabel
- 453
Silverstein F E, Faich G, Goldstein J L. et al .
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for
osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled
trial. Celecoxib Long-term Arthritis Safety Study.
JAMA.
2000;
284
1247-1255
MissingFormLabel
- 454
Bombardier C, Laine L, Reicin A. et al .
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients
with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med.
2000;
343
1520-1528
MissingFormLabel
- 455
Chan F K, Hung L C, Suen B Y. et al .
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer
bleeding in patients with arthritis.
N Engl J Med.
2002;
347
2104-2110
MissingFormLabel
- 456
Chan F K, Hung L C, Suen B Y. et al .
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results
of a randomized double-blind trial.
Gastroenterology.
2004;
127
1038-1043
MissingFormLabel
- 457
Hooper L, Brown T J, Elliott R. et al .
The effectiveness of five strategies for the prevention of gastrointestinal toxicity
induced by non-steroidal anti-inflammatory drugs: systematic review.
BMJ.
2004;
329
948
MissingFormLabel
- 458
Kearney P M, Baigent C, Godwin J. et al .
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory
drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.
BMJ.
2006;
332
1302-1308
MissingFormLabel
- 459
Rostom A, Muir K, Dube C. et al .
Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic
review.
Clin Gastroenterol Hepatol.
2007;
5
818-828, 828 e811 – 815; quiz 768
MissingFormLabel
- 460
Chan F K, Wong V W, Suen B Y. et al .
Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention
of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised
trial.
Lancet.
2007;
369
1621-1626
MissingFormLabel
- 461
Goldstein J L, Cryer B, Amer F. et al .
Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized,
double-blind, endoscopic trial.
Clin Gastroenterol Hepatol.
2007;
5
1167-1174
MissingFormLabel
- 462
Stack W A, Atherton J C, Hawkey G M. et al .
Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding.
Aliment Pharmacol Ther.
2002;
16
497-506
MissingFormLabel
- 463
Chan F K, To K F, Wu J C. et al .
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting
long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.
Lancet.
2002;
359
9-13
MissingFormLabel
- 464
Lai K C, Lau C S, Ip W Y. et al .
Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers
in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial.
Aliment Pharmacol Ther.
2003;
17
799-805
MissingFormLabel
- 465
Vergara M, Catalan M, Gisbert J P. et al .
Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic
ulcer in NSAID users.
Aliment Pharmacol Ther.
2005;
21
1411-1418
MissingFormLabel
- 466
Lai K C, Lam S K, Chu K M. et al .
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal
anti-inflammatory drug users – a randomized trial.
Aliment Pharmacol Ther.
2003;
18
829-836
MissingFormLabel
- 467
Hawkey C J, Tulassay Z, Szczepanski L. et al .
Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal
anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention.
Lancet.
1998;
352
1016-1021
MissingFormLabel
- 468
Chan F K, Chung S C, Suen B Y. et al .
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter
pylori infection who are taking low-dose aspirin or naproxen.
N Engl J Med.
2001;
344
967-973
MissingFormLabel
- 469
Weil J, Colin-Jones D, Langman M. et al .
Prophylactic aspirin and risk of peptic ulcer bleeding.
BMJ.
1995;
310
827-830
MissingFormLabel
- 470
Kelly J P, Kaufman D W, Jurgelon J M. et al .
Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated
or buffered product.
Lancet.
1996;
348
1413-1416
MissingFormLabel
- 471
Slattery J, Warlow C P, Shorrock C J. et al .
Risks of gastrointestinal bleeding during secondary prevention of vascular events
with aspirin – analysis of gastrointestinal bleeding during the UK-TIA trial.
Gut.
1995;
37
509-511
MissingFormLabel
- 472
Yeomans N D, Lanas A I, Talley N J. et al .
Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective
doses of aspirin.
Aliment Pharmacol Ther.
2005;
22
795-801
MissingFormLabel
- 473
Lanas A, Fuentes J, Benito R. et al .
Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients
taking low-dose aspirin.
Aliment Pharmacol Ther.
2002;
16
779-786
MissingFormLabel
- 474
Lai K C, Lam S K, Chu K M. et al .
Lansoprazole for the prevention of recurrences of ulcer complications from long-term
low-dose aspirin use.
N Engl J Med.
2002;
346
2033-2038
MissingFormLabel
- 475
Chan F K, Ching J Y, Hung L C. et al .
Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding.
N Engl J Med.
2005;
352
238-244
MissingFormLabel
- 476
Lai K C, Chu K M, Hui W M. et al .
Esomeprazole with aspirin versus clopidogrel for prevention of recurrent gastrointestinal
ulcer complications.
Clin Gastroenterol Hepatol.
2006;
4
860-865
MissingFormLabel
- 477
Hallas J, Dall M, Andries A. et al .
Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal
bleeding: population based case-control study.
BMJ.
2006;
333
726
MissingFormLabel
- 478
Summers R W, Switz D M, Sessions J T. et al .
National Cooperative Crohn’s Disease Study: results of drug treatment.
Gastroenterology.
1979;
77
847-869
MissingFormLabel
- 479
Malchow Jr H, Ewe K, Brandes J W. et al .
European Cooperative Crohn’s Disease Study (ECCDS): results of drug treatment.
Gastroenterology.
1984;
86
249-266
MissingFormLabel
- 480
Guslandi M, Tittobello A.
Symptomatic response to omeprazole in inflammatory bowel disease.
J Clin Gastroenterol.
1996;
22
159-160
MissingFormLabel
- 481
Dickinson J B.
Is omeprazole helpful in inflammatory bowel disease?.
J Clin Gastroenterol.
1994;
18
317-319
MissingFormLabel
- 482
Cheung A N, Ng I O.
Cytomegalovirus infection of the gastrointestinal tract in non-AIDS patients.
Am J Gastroenterol.
1993;
88
1882-1886
MissingFormLabel
- 483
Dorigo-Zetsma J W, Meer J T, Tersmette van der M. et al .
Value of laboratory investigations in clinical suspicion of cytomegalovirus-induced
upper gastrointestinal tract ulcerations in HIV-infected patients.
J Med Virol.
1996;
49
29-33
MissingFormLabel
- 484
Peter A, Telkes G, Varga M. et al .
Endoscopic diagnosis of cytomegalovirus infection of upper gastrointestinal tract
in solid organ transplant recipients: Hungarian single-center experience.
Clin Transplant.
2004;
18
580-584
MissingFormLabel
- 485
Pruitt B A, Foley F D, Moncrief J A.
Curling’s ulcer: a clinical-pathology study of 323 cases.
Ann Surg.
1970;
172
523-539
MissingFormLabel
- 486
Cook D J, Fuller H D, Guyatt G H. et al .
Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical
Care Trials Group.
N Engl J Med.
1994;
330
377-381
MissingFormLabel
- 487
Cook D J, Reeve B K, Guyatt G H. et al .
Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses.
Jama.
1996;
275
308-314
MissingFormLabel
- 488
Tryba Jr M, Cook D.
Current guidelines on stress ulcer prophylaxis.
Drugs.
1997;
54
581-596
MissingFormLabel
- 489
Rosen H R, Vlahakes G J, Rattner D W.
Fulminant peptic ulcer disease in cardiac surgical patients: pathogenesis, prevention,
and management.
Crit Care Med.
1992;
20
354-359
MissingFormLabel
- 490
Janicki T, Stewart S.
Stress-ulcer prophylaxis for general medical patients: a review of the evidence.
J Hosp Med.
2007;
2
86-92
MissingFormLabel
Prof. Dr. Wolfgang Fischbach
Medizinische Klinik II und Klinik für Palliativmedizin, Klinikum Aschaffenburg, Akad.
Lehrkrankenhaus der Universität Würzburg
Am Hasenkopf
63739 Aschaffenburg
Telefon: ++ 49/60 21/32 30 10
Fax: 49/60 21/32 30 31
eMail: med2-aschaffenburg@t-online.de